CA2512926C - Methods and compositions for inhibition of angiogenesis - Google Patents
Methods and compositions for inhibition of angiogenesis Download PDFInfo
- Publication number
- CA2512926C CA2512926C CA2512926A CA2512926A CA2512926C CA 2512926 C CA2512926 C CA 2512926C CA 2512926 A CA2512926 A CA 2512926A CA 2512926 A CA2512926 A CA 2512926A CA 2512926 C CA2512926 C CA 2512926C
- Authority
- CA
- Canada
- Prior art keywords
- angiogenesis
- disease
- compounds
- present
- thalidomide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
Description
METHODS AND COMPOSITIONS
FOR INHIBITION OF ANGIOGENESIS
Technical Field The present invention relates to methods and compositions for preventing unwanted angiogenesis in a human or s animal. More particularly, the present invention relates to a method for preventing unwanted angiogenesis, particularly in angiogenesis dependent or associated diseases, by administration of compounds such as thalidomide and related compounds.
Background of the Invention 1o As used herein, the tenor "angiogenesis" means the generation of new blood vessels into a tissue or organ. Under normal physiological conditions, humans or animals only undergo angiogenesis in very specific restricted situations. For example.
angiogenesis is nonmaily observed in wound healing, fetal and i5 embryonal development and formation of the corpus luteum.
endometrium and placenta. The control of angiogenesis is a highly regulated system of angiogenic stimulators and inhibitors.
The control of angiogenesis has been found to be altered in certain disease states and, in many cases, the pathological damage associated with the disease is related to the uncontrolled angiogenesis.
Both controlled and uncontrolled angiogenesis are s thought to proceed in a similar manner. Endothelial cells and pericytes, surrounded by a basement membrane, form capillary blood vessels. Angiogenesis begins with the erosion of the basement membrane by enzymes released by endothelial cells and leukocytes. The endothelial cells, which line the lumen of blood io vessels, then protrude through the basement membrane.
Angiogenic stimulants induce the endothelial cells to migrate through the eroded basement membrane. The migrating cells form a "sprout" off the parent blood vessel, where the endothelial cells undergo mitosis and proliferate. The endothelial sprouts is merge with each other to form capillary loops, creating the new blood vessel. In the disease state, prevention of angiogenesis could avert the damage caused by the invasion of the new microvascular system.
Persistent, unregulated angiogenesis occurs in a Zo multiplicity of disease states, tumor metastasis and abnormal growth by endothelial cells and supports the pathological damage seen in these conditions. The diverse pathological states created due to unregulated angiogenesis have been grouped together as angiogenic dependent or angiogenic associated diseases. Therapies 2s directed at control of the angiogenic processes could lead to the abrogation or mitigation of these diseases.
One example of a disease mediated by angiogenesis is ocular neovascular disease. This disease is characterized by invasion of new blood vessels into the structures of the eye such 30 as the retina or cornea. It is the most common cause of blindness and is involved in approximately twenty eye diseases. In age-related macular degeneration, the associated visual problems are 'caused by an ingrowth of chorioidal capillaries through defects in Bruch's membrane with proliferation of fibrovascular tissue 3s beneath the retinal pigment epithelium. Angiogenic damage is also associated with diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma and retrolental fibroplasia. Other diseases associated with corneal neovascularization include, but are not limited to, epidemic s keratoconjunctivitis, Vitamin A deficiency, contact lens overwear, atopic keratitis, superior limbic keratitis, pterygium keratitis sicca, sjogrens, acne rosacea, phylectenulosis, syphilis, Mycobacteria infections, lipid degeneration, chemical burns, bacterial ulcers, fungal ulcers, Herpes simplex infections, Herpes ~o zoster infections, protozoan infections, Kaposi sarcoma, Mooren ulcer, Terrien's marginal degeneration, mariginal keratolysis, rheumatoid arthritis, systemic lupus, polyarteritis, trauma, Wegeners sarcoidosis, Scleritis, Steven's Johnson disease, periphigoid radial keratotomy, and corneal graph rejection.
is Diseases associated with retinal/choroidal neovascularization include, but are not limited to, diabetic retinopathy, macular degeneration, sickle cell anemia, sarcoid, syphilis, pseudoxanthoma elasticum, Pagets disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic zo uveitis/vitritis, mycobacterial infections, Lyme's disease, systemic lupus erythematosis, retinopathy of prematurity, Eales disease, Bechets disease, infections causing a retinitis or choroiditis, presumed ocular histoplasmosis, Bests disease, myopia, optic pits, Stargarts disease, pats planitis, chronic retinal detachment, 2s hyperviscosity syndromes, toxoplasmosis, trauma and post-laser complications. Other diseases include, but are not limited to, diseases associated with rubeosis (neovasculariation of the angle) and diseases caused by the abnormal proliferation of fibrovascular or fibrous tissue including all forms of proliferative 3o vitreoretinopathy.
Another disease in which angiogenesis is believed to be involved is rheumatoid arthritis. The blood vessels in the synovial lining of the joints undergo angiogenesis. In addition to forming new vascular networks, the endothelial cells release factors and reactive oxygen species that lead to pannus growth and cartilage destruction. The factors involved in angiogenesis may actively contribute to, and help maintain, the chronically inflamed state of rheumatoid arthritis.
Factors associated with angiogenesis may also have a s role in osteoarthritis. The activation of the chondrocytes by angiogenic-related factors contributes to the destruction of the joint. At a later stage, the angiogenic factors would promote new bone formation. Therapeutic intervention that prevents the bone destruction could halt the progress of the disease and provide io relief for persons suffering with arthritis.
Chronic inflammation may also involve pathological angiogenesis. Such disease states as ulcerative colitis and Crohn's disease show histological changes with the ingrowth of new blood vessels into the inflamed tissues. Bartonellosis, a bacterial is infection found in South America, can result in a chronic stage that is characterized by proliferation of vascular endothelial cells.
.Another pathological role associated with angiogenesis is found in atherosclerosis. The plaques formed within 'the lumen of blood vessels have been shown to have angiogenic stimulatory activity.
2o One of the most frequent angiogenic diseases of childhood is the hemangioma. In most cases, the tumors are benign and regress without intervention. In more severe cases, the tumors progress to large cavernous and infiltrative forms and create clinical complications. Systemic forms of hemangiomas, 2s the hemangiomatoses, have a high mortality rate.
Therapy-resistant hemangiomas exist that cannot be treated with therapeutics currently in use.
Angiogenesis is also responsible for damage found in hereditary diseases such as Osler-Weber-Rendu disease, or 3o hereditary hemorrhagic telangiectasia. This is an inherited disease characterized by multiple small angiomas, tumors of blood or lymph vessels. The angiomas are found in the skin and mucous membranes, often accompanied by epistaxis (nosebleeds) or gastrointestinal bleeding and sometimes with pulmonary or 3s hepatic arteriovenous fistula.
FOR INHIBITION OF ANGIOGENESIS
Technical Field The present invention relates to methods and compositions for preventing unwanted angiogenesis in a human or s animal. More particularly, the present invention relates to a method for preventing unwanted angiogenesis, particularly in angiogenesis dependent or associated diseases, by administration of compounds such as thalidomide and related compounds.
Background of the Invention 1o As used herein, the tenor "angiogenesis" means the generation of new blood vessels into a tissue or organ. Under normal physiological conditions, humans or animals only undergo angiogenesis in very specific restricted situations. For example.
angiogenesis is nonmaily observed in wound healing, fetal and i5 embryonal development and formation of the corpus luteum.
endometrium and placenta. The control of angiogenesis is a highly regulated system of angiogenic stimulators and inhibitors.
The control of angiogenesis has been found to be altered in certain disease states and, in many cases, the pathological damage associated with the disease is related to the uncontrolled angiogenesis.
Both controlled and uncontrolled angiogenesis are s thought to proceed in a similar manner. Endothelial cells and pericytes, surrounded by a basement membrane, form capillary blood vessels. Angiogenesis begins with the erosion of the basement membrane by enzymes released by endothelial cells and leukocytes. The endothelial cells, which line the lumen of blood io vessels, then protrude through the basement membrane.
Angiogenic stimulants induce the endothelial cells to migrate through the eroded basement membrane. The migrating cells form a "sprout" off the parent blood vessel, where the endothelial cells undergo mitosis and proliferate. The endothelial sprouts is merge with each other to form capillary loops, creating the new blood vessel. In the disease state, prevention of angiogenesis could avert the damage caused by the invasion of the new microvascular system.
Persistent, unregulated angiogenesis occurs in a Zo multiplicity of disease states, tumor metastasis and abnormal growth by endothelial cells and supports the pathological damage seen in these conditions. The diverse pathological states created due to unregulated angiogenesis have been grouped together as angiogenic dependent or angiogenic associated diseases. Therapies 2s directed at control of the angiogenic processes could lead to the abrogation or mitigation of these diseases.
One example of a disease mediated by angiogenesis is ocular neovascular disease. This disease is characterized by invasion of new blood vessels into the structures of the eye such 30 as the retina or cornea. It is the most common cause of blindness and is involved in approximately twenty eye diseases. In age-related macular degeneration, the associated visual problems are 'caused by an ingrowth of chorioidal capillaries through defects in Bruch's membrane with proliferation of fibrovascular tissue 3s beneath the retinal pigment epithelium. Angiogenic damage is also associated with diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma and retrolental fibroplasia. Other diseases associated with corneal neovascularization include, but are not limited to, epidemic s keratoconjunctivitis, Vitamin A deficiency, contact lens overwear, atopic keratitis, superior limbic keratitis, pterygium keratitis sicca, sjogrens, acne rosacea, phylectenulosis, syphilis, Mycobacteria infections, lipid degeneration, chemical burns, bacterial ulcers, fungal ulcers, Herpes simplex infections, Herpes ~o zoster infections, protozoan infections, Kaposi sarcoma, Mooren ulcer, Terrien's marginal degeneration, mariginal keratolysis, rheumatoid arthritis, systemic lupus, polyarteritis, trauma, Wegeners sarcoidosis, Scleritis, Steven's Johnson disease, periphigoid radial keratotomy, and corneal graph rejection.
is Diseases associated with retinal/choroidal neovascularization include, but are not limited to, diabetic retinopathy, macular degeneration, sickle cell anemia, sarcoid, syphilis, pseudoxanthoma elasticum, Pagets disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic zo uveitis/vitritis, mycobacterial infections, Lyme's disease, systemic lupus erythematosis, retinopathy of prematurity, Eales disease, Bechets disease, infections causing a retinitis or choroiditis, presumed ocular histoplasmosis, Bests disease, myopia, optic pits, Stargarts disease, pats planitis, chronic retinal detachment, 2s hyperviscosity syndromes, toxoplasmosis, trauma and post-laser complications. Other diseases include, but are not limited to, diseases associated with rubeosis (neovasculariation of the angle) and diseases caused by the abnormal proliferation of fibrovascular or fibrous tissue including all forms of proliferative 3o vitreoretinopathy.
Another disease in which angiogenesis is believed to be involved is rheumatoid arthritis. The blood vessels in the synovial lining of the joints undergo angiogenesis. In addition to forming new vascular networks, the endothelial cells release factors and reactive oxygen species that lead to pannus growth and cartilage destruction. The factors involved in angiogenesis may actively contribute to, and help maintain, the chronically inflamed state of rheumatoid arthritis.
Factors associated with angiogenesis may also have a s role in osteoarthritis. The activation of the chondrocytes by angiogenic-related factors contributes to the destruction of the joint. At a later stage, the angiogenic factors would promote new bone formation. Therapeutic intervention that prevents the bone destruction could halt the progress of the disease and provide io relief for persons suffering with arthritis.
Chronic inflammation may also involve pathological angiogenesis. Such disease states as ulcerative colitis and Crohn's disease show histological changes with the ingrowth of new blood vessels into the inflamed tissues. Bartonellosis, a bacterial is infection found in South America, can result in a chronic stage that is characterized by proliferation of vascular endothelial cells.
.Another pathological role associated with angiogenesis is found in atherosclerosis. The plaques formed within 'the lumen of blood vessels have been shown to have angiogenic stimulatory activity.
2o One of the most frequent angiogenic diseases of childhood is the hemangioma. In most cases, the tumors are benign and regress without intervention. In more severe cases, the tumors progress to large cavernous and infiltrative forms and create clinical complications. Systemic forms of hemangiomas, 2s the hemangiomatoses, have a high mortality rate.
Therapy-resistant hemangiomas exist that cannot be treated with therapeutics currently in use.
Angiogenesis is also responsible for damage found in hereditary diseases such as Osler-Weber-Rendu disease, or 3o hereditary hemorrhagic telangiectasia. This is an inherited disease characterized by multiple small angiomas, tumors of blood or lymph vessels. The angiomas are found in the skin and mucous membranes, often accompanied by epistaxis (nosebleeds) or gastrointestinal bleeding and sometimes with pulmonary or 3s hepatic arteriovenous fistula.
Angiogenesis is prominent in solid tumor formation and metastasis. Angiogenic factors have been found associated with several solid tumors such as rhabdomyosarcomas, retinoblastoma, Ewing sarcoma, neuroblastoma, and s osteosarcoma. A tumor cannot expand without a blood supply to provide nutrients and remove cellular wastes. Tumors in which angiogenesis is important include solid tumors, and benign tumors such as acoustic neuroma, neurofibroma, trachoma and pyogenic granulomas. Prevention of angiogenesis could halt the growth of io these tumors and the resultant damage to the animal due to the presence of the tumor.
It should be noted that angiogenesis has been associated with blood-born tumors such as leukemias, any of various acute or chronic neoplastic diseases of the bone marrow is in which unrestrained proliferation of white blood cells occurs, usually accompanied by anemia, impaired blood clotting, and enlargement of the lymph nodes, Iiver, and spleen. It is believed that angiogenesis plays a role in the abnormalities in the bone marrow that give rise to leukemia-like tumors.
2o Angiogenesis is important in two stages of tumor metastasis. The first stage where angiogenesis stimulation is important is in the vascularization of the tumor which allows tumor cells to enter the blood stream and to circulate throughout the body. After the tumor cells have left the primary site, and zs have settled into the secondary, metastasis site, angiogenesis must occur before the new tumor can grow and expand. Therefore, prevention of angiogenesis could lead to the prevention of metastasis of tumors and possibly contain the neoplastic growth at the primary site.
3o Knowledge of the role of angiogenesis in the maintenance and metastasis of tumors has led to a prognostic indicator for breast cancer. The amount of neovascularization found in the primary tumor was determined by counting the microvessel density in the area of the most intense 3s neovascularization in invasive breast carcinoma. A high level of microvessel density was found to correlate with tumor recurrence. Control of angiogenesis by therapeutic means could possibly lead to cessation of the recurrence of the tumors.
Angiogenesis is also involved in normal physiological s processes such as reproduction and wound healing. Angiogenesis is an important step in ovulation and also in implantation of the blastula after fertilization. Prevention of angiogenesis could be used to induce amenorrhea, to block ovulation or to prevent implantation by the blastula.
io In wound healing, excessive repair or fibroplasia can be a detrimental side effect of surgical procedures and may be caused or exacerbated by angiogenesis. Adhesions are a frequent complication of surgery and lead to problems such as small bowel obstruction.
is Several kinds of compounds have been used to prevent angiogenesis. Taylor et al. have used protamine to inhibit angiogenesis, see Taylor et al., Nature 297:307 (1982). The toxicity of protamine limits its practical use as a therapeutic.
Folkman et a1. have disclosed the use of heparin and steroids to 2o control angiogenesis. See Folkman et al., Science 221:719 ( 1983) and U.S. Patent Nos. 5,001,116 and 4,994,443. Steroids, such as tetrahydrocortisol, which lack gluco and mineral corticoid activity, have been found to be angiogenic inhibitors.
Other factors found endogenously in animals, such as 2s a 4 kDa glycoprotein from bovine vitreous humor and a cartilage derived factor, have been used to inhibit angiogenesis. Cellular factors such as interferon inhibit angiogenesis. For example, interferon a or human interferon Q has been shown to inhibit tumor-induced angiogenesis in mouse dermis stimulated by 3o human neoplastic cells. Interferon Li is also a potent inhibitor of angiogenesis induced by allogeneic spleen cells. See Sidky et al., Cancer Research 47:5155-5161 (1987). Human recombinant a interferon (alpha/A) was reported to be successfully used in the treatment of pulmonary hemangiomatosis, an angiogenesis-induced disease. See White et al., New England J. Med.
320:1197-1200 ( 1989).
Other agents which have been used to inhibit angiogenesis include ascorbic acid ethers and related compounds.
s See Japanese Kokai Tokkyo Koho No. 58-131978. Sulfated polysaccharide DS 4152 also shows angiogenic inhibition. See Japanese Kokai Tokkyo Koho No. 63-119500. A fungal product.
fumagillin, is a potent angiostatic agent in vitro. The compound is toxic in vivo, but a synthetic derivative, AGM 12470, has been io used in vivo to treat collagen II arthritis. Fumagillin and O-substituted fumagillin derivatives are disclosed in EPO
Publication Nos. 0325199A2 and 0357061 A 1.
PCT Application No. WO 92/14455 to Kaplan et al.
is directed to a method for controlling abnormal concentration of is TNF-a by administering thalidomide or thalidomide derivatives to a patient with toxic concentrations of TNF-a.
The above compounds are either topical or injectable therapeutics. Therefore, there are drawbacks to their use as a general angiogenic inhibitor and lack adequate potency. For 2o example, in prevention of excessive wound healing, surgery on internal body organs involves incisions in various structures contained within the body cavities. These wounds are not accessible to local applications of angiogenic inhibitors. Local delivery systems also involve frequent dressings which are 2s impracticable for internal wounds, and increase the risk of infection or damage to delicate granulation tissue for surface wounds.
Thus, a method and composition are needed that are capable of inhibiting angiogenesis and which are easily 3o administered. A simple and efficacious method of treatment would be through the oral route. If an angiogenic inhibitor could be given by an oral route, the many kinds of diseases discussed above,' and other angiogenic dependent pathologies, could be treated easily. The optimal dosage could be distributed in a form 3s that the patient could self-administer.
_8_ Sl~Bty 0f tjlC lilieilt1011 In accordance with the preset invention, compositions and mahods are provided that are effecxive in inhibiting unwanted aqgiogenesis. These compositions are easily administered by different routes including oral and can be given in dosages that are safe and provide angiogenic inhibition at internal sites. The present invention provides a method of treating mammalian diseases mediated by undesired and uncontrolled angiogenesis by administering a composition comprising an anti-angiogenic compound in a dosage sufficient to inhibit angiogenesis.
The present invention also includes angiogenic inhibiting compounds that contain an epoxide group. These angiogenic inhibiting compounds can be administered to a human or animal alone or with epoxide hydrolase inhibiting .
The present invention is especially useful for treating cxrtain ocular neovascular diseases such as macular degeneration. The compounds which are contemplated as part of the present invention preferably can be given orally to the patient and thereby halt the progression of the disease. Other diseases that can be treated using the present invention are diabetic retinopathy, neovascular glaucoma and retrolental fibroplasia.
Accordingly, the present invention in one aspect seeks to provide a compound a~xl the use thereof to inhibit unwanted angiogeaesis in a human or animal.
the present invention seeks to provide a composition for inhibiting angiogenesis by oral administration of the composition.
Further still the present invention seeks to provide a treatment for disease's mediatod by angiogenesis.
Still further the present invention soaks to provide a treatment for ~cttlar degeneration.
Yet another aspect of the present invention seeks to provide a treatmenx for all forma of proliferative vitreoretinopathy including those forms not associated with diabetes.
Further again the present invention seeks to provide a treatme~ for solid tumors.
Still further the present invention seeks to provide a composition and use thereof for the treatment of blood-born tumors such as leukemia.
It is another object of the present invention to provide a composition and use thereof for the treatment of hemangioma., It is another object of the present invention to provide a composition and use thereof for the treatment of retrolental fibroplasia.
It is another object of the present invention to provide a composition and use thereof for the treatment of psoriasis.
It is another object of the presetrt invention to provide a composition and use . thereof for the treatment of Kaposi's sarcoma.
It is another object of the present invention to provide a composition and use thereof for the treatment of Crohn's diseases.
It is another object of the present invention to provide a method and composition for the treatment of diabetic retinopathy.
The invention to which the claims herein are directed is to the use of thalidomide for the treatment of angioge~sis or unwanted angiogenesis or for the inhibiting or preventing angiogenesis.
Further the invention contemplates the use of thalidomide in the manufacture of a medicament for the treatment of an undesired angiogenesis, umvanted angiogenesis, the inhibiting of angiogenesis or the prevention of angiogenesis.
Other features and advantages of the invention will be apparent from the following description of preferred embodiments thereof.
These and other aspects, features and advantages of the present invention will becott~e apparent after a review of the following detailed description of the disclosed embodiments and the appended claims.
Brief Description of the Figures Figures 1 through 3 are a listing of representative compounds in the genus represented by the following general formulas:
s A) R' Rs ~R
R3 ,/Rg R9 Rs B) R' 1 Rs \R8-R9 Ra C) R
js R Re_R9 Ra to Figure 4 is a listing of representative compounds in the genus represented by the following general formula:
O
R''Z ~N-'R2a is Figure 5 is a listing of representative compounds in the genus represented by the following general formula:
O~C~OHO
i-X
H
Figure 6 shows the effect of thalidomide and EM 12 on angiogenesis in a rabbit cornea model of angiogenesis.
Figure 7 shows the effect of thalidomide on the area s of corneal vascularization in a rabbit cornea model of angiogenesis.
Detailed Description The present invention includes compositions and io methods for the treatment of diseases that are mediated by angiogenesis. One embodiment of the present invention is the use of thalidomide or the metabolites of thalidomide as disclosed herein to inhibit unwanted angiogenesis. The present invention _ also includes compounds which cause dysmelia is the developing is fetus and have anti-angiogenic activity. The present invention comprises a method of treating undesired angiogenesis in a human or animal comprising the steps of administering to the human or animal with the undesired angiogenesis a composition comprising an effective amount of a teratogenic compound that is anti 2o angiogenic.
Compounds that can be used in accordance with the present invention include compounds included in the following general formulae. Examples of compounds that have anti-angiogenic properties having one of the following three 2s formulae (A), (B), or (C):
A) R~ 1 Rs ~R
R3 /Rg- R9 Ra B) R i Rs RQ
C) R i Rs R 'Rs _ R9 Ra In the above formulae A), B), and C), R1, R2, R3 and R.~ can be selected from: -H; -OH; =O, straight chained and branched alkanes, alkenes, alkynes; cyclic alkanes, alkenes, and alkynes;
io combinations of cyclic and acyclic alkanes, alkenes, and alkynes;
alcohol, aldehyde, ketone, carboxylic acid, ester, or ether moieties in combination with acyclic, cyclic, or combination acyclic/cyclic moieties; aza; amino; -XOn or -O-XOn, (where X=N and n=2; X=S and n=2 or 3; or X=P and n=1-3]; and is halogens; R5, R(, R7, and Rg are each independently selected from:
-C-Rio: 'N-Rto:
or -O- where Y is optional and is the same as defined above for R l ; and R 1 p is the same as defined above for R l , or (where Y is absent) R 1 p is =O; and R9 is a moiety having formula D), E), F), G) or H):
D) F) ~t~-Rts -Rtt-Rt2 -R11/ Rta Rta'_'Rm Rtb Rts s E) G) ~Rt3 Rt2 W
R~~
~Rtz-Rta -RR
Rtt l tt \ ~ 'Rts Rt3-Rts R1~~Rtb where each of Rl 1 - R17 is (independently) the same as defined above for R5;
io I~
Rt8 -C-Rt9 i Rio where R 1 g, R 19 and R2p are, independently selected from ° ° q q -H, CH3, -C-OH,-C-NH2.-(CHZ),~ C-OH, or-(CH2)"-C-NH,, is and n=1 to 4.
Accordingly, another aspect of the present invention features inhibiting angiogenesis in a mammal by administering a therapeutic composition comprising one of the above-described compounds in a dosage sufficient to inhibit angiogenesis In preferred embodiments, the compound has formula B), where RS and R( are selected from the group consisting of:
-CHI , -CHOH, and~CO
s and R9 has formula F) or H); and R14 and RI6 are selected from the group consisting of:
R, I
;CH2, ;CHOH, or- ~-;and Rls and is -O-, or-N-, O
where R21 is -H, -CH3, or -OH. Specific preferred compounds according to this aspect of the present invention include io thalidomide, its precursors, metabolites and analogs. Particular analogs include EM-12, N-phthaloyl-DL-glutamic acid (PGA) or N-phthaloyl-DL-glutamine anhydride. Examples of compounds that are members of this genus are listed in Figures 1 through 3.
It is to be understood that the compounds included as part of the is present invention are not to be limited to those compounds shown in Figures 1 through 3 and include all other compounds that are members of the genus described by the general formulas herein.
Compounds of the following formula that have anti-angiogenic properties:
O
R2' \ \N-R2a \v 2s where R22 and R23 are (independently), -H, -F, -C1, -Br, -I, -CH3, or -CH2 -CH3; and R24 is -H, -CH3, or -CH2 -CH3.
The present invention also features inhibiting angiogenesis in a mammal by administering a compound according to the above formulae in a dosage sufficient to inhibit angiogenesis. Examples of specific compounds that are members of this genus are listed in Figure 4.
Angiogenesis inhibition hydrolysis products of thalidomide having the following general formula can be used in practicing the present invention:
~O~ ,OH
I
H
where X is R6 as defined above, or -X
O I O
X is R25-C-C-(CH2)n-C-R26 io and R25 and R26 are, independently, -OH, -H, or NH2, and n=1 through 4. Examples of such compounds are shown in l figure 5.
Angiogenesis inhibition compounds having the following general formula can be used in practicing the present invention:
(I) O O R" (II) I
R' / N
/N O
O ( O \ X
~ (a) CH,-N O
wherein compounds of structure (I), wherein R is selected from the group consisting of hydrogen, alkyl radicals of 1 to 6 carbon atoms, the phenyl radical, and the benzyl radical;
2o and wherein R' is selected from the group consisting of the phthalimido radical and the succinimido radical and of structure (II), wherein X is CH2 or C=O; R" is H, -CH2CH3, -C6H5, -CH2C6H5, -CH2CH=CH2, or (a) and hydrolysis products of the compounds wherein R" is H and the piperidino ring or both the 2s piperidino and the imido ring are hydrolyzed.
1.
Another set of compounds that are considered part of the present invention are the epoxides of thalidomide, EM-12 and EM-138. Representative epoxide compounds are shown as follows:
O ~ C
i CN O I N O
\ Cr N; O C N\
O O H O O H
Epoxides of thalidomide O O O
C
\ ~ ~N ~O I N N~O
O NH O O H
to Epoxides of EM 12 O O
I II
O o ~~OH ~ C~OH
C \ Cv I N I _N
\ 1 _-_O O I =O
OH OH
Epoxides of EM 138 It should be understood that the epoxide can be attached at the 6,1 site on the benzene ring, the 1,2 site, the 2,3 site 3,4 or the 4,S site. All of these compounds are contemplated as part of the present invention.
2o The epoxides of the thalidomide, EM-12, and EM 138 can be hydrolized to the following compounds:
_I7_ O O
HO / I ~ HO
N O ~ N ~O
\ C N HO
C N
O O H O O H
O O
HO / C~ HO
N ~O ~ N ~O
N HO \ N
O/ H O~ H
O
OH
O
HO / C HO / C N
HO \ I OH
O
to It is to be understood that the hydroxyl group can be on carbons I, 2, 3, 4, 5 and 6 of the benzene ring. Also contemplated as part of the present invention are dihydroxyl compounds wherein the two hydroxyl groups are located bis to each other on carbons 1, 2, 3, 5 and 6 of the above compounds.
i5 The epoxides, the hydrolysis products of the epoxides, and the hydrolysis products of the thalidomide are alI contemplated to be part of the present invention.
It is known that epoxides are hydrolized by a group . of enzymes known as epoxide hydrolases. There is a class of 2o compounds which are epoxide hydrolase inhibitors. Examples of these compounds are valpromide (2-propylpentanamide) and valproic acid (2-propylpentanoic acid). Because epoxides are - l8-important angiogenesis inhibitors, it is contemplated as part of the present invention, compositions comprising any of the angiogenesis inhibitors compounds recited herein in combination with epoxide hydrolase inhibitors. The epoxide hydrolase s inhibitors can be administered to a human or animal together or sequentially. The expoxide group appears to be an important substituent common to several angiogenesis inhibitors. The use of epoxide hydrolase inhibitors to potentiate the activity of any angiogenesis inhibitor containing an epoxide is contemplated as to part of the present invention. For example, the epoxide hydrolase inhibitors can be administered with the following epoxide-containing anti-angiogenesis compounds: AGM 1470, Eponimycin, microbial metabolites of Scolecobasidium arenarium designated f/2015, fr/111142 and fr/18487. See Oikawa, is Biochem Biophys. Res. Comm, Vol. 81:1070 (1971) and Otsuka, J. Microbial. Biotech., Vol 1:163 (1991).
It is contemplated as an embodiment of the present invention the use of the epoxide containing angiogenesis inhibitors with or without epoxide hydrolase inhibitors as a treatment for zo diseases mediated by elevated or toxic levels of TNF-a. TNF-a has been recognized as manifesting a dose dependent toxicity. If present at low levels for a long period of time, TNF-a can result in cachexia. Cachexia is a general weight loss and wasting occurring in the course of some chronic diseases such as cancer, 2s opportunistic infections of AIDS, inflammatory diseases, parasitic diseases, tuberculosis, and high dose IL-2 therapy. The epoxide containing angiogenesis inhibitors, with or without epoxide hydrolase inhibitors, are also effective in treating diseases such as septic shock, leprosy and graph vs. host disease.
3o Other embodiments are within the present invention.
For example, other dysmelia-causing compounds can be used according to the present invention, e.g. 4-methylphthalic acid, pyridoxine, vasopressin, acetazolamide, or a compound having the following formula (where R= H, -OH, or -CH3):
O
I
R
Other compounds which are teratogens, such as valproic acid (2-propylpentanoic acid), the retinoids, such as cis-retinoic acid, and rifampin may also be used in accordance with the invention.
s In summary, the preferred compounds are thalidomide, as well as analogs, hydrolysis products, metabolites and precursors of thalidomide that are teratogenic, and, more specifically, that cause dismelia. However, it is to be understood that it is not necessary for a compound to have both teratogenic io activity and angiogenesis inhibiting activity to be considered part of the present invention. Dysmelia-causing compounds can be identified by the general procedures of Helm, Ar:,neimittle-forschung. 31(i/6):941-949 (1981), in which rabbit pups are examined after exposure to the compound in utero. The is compounds can generally be purchased, e.g., from Andrulis Pharmaceuticals, Beltsville, MD, or synthesized according to known procedures. It is to be understood that the compounds of the present invention can exist as enantiomers and that the racemic mixture of enantiomers or the isolated enantiomers are 2o all considered as within the scope of the present invention.
Many of the compounds that are contemplated as part of the present invention can be enriched in optically active enantiomers of the compounds specified above. Specifically, Blaschke has reported that the S enanantiomers may be ~s disproportionately responsible for the dismelia-producing effect of these compounds. See, generally Blaschke, Ar~neimittelforschung 29:1640-1642 (1979). The above described articles generally describe procedures to obtain optically active preparations of the compounds of interest. See.
3o e.g. Shealy et al., Chem. Indus. 1030 ( 1965); and Casini et al., Farmaco Ed. Sci. 19:563 ( 1964). v The compounds described above can be provided as pharmaceutically acceptable formulations using formulation methods known to those of ordinary skill in the art. These s formulations can be administered by standard routes. In general, the combinations may be administered by the topical.
transdermal, oral, rectal or parenteral (e.g., intravenous, subcutaneous or intramuscular) route. In addition, the combinations may be incorporated into biodegradable polymers io allowing for sustained release of the compound, the polymers being implanted in the vicinity of where drug delivery is desired, for example, at the site of a tumor. The biodegradable polymers and their use are described, for example, in detail in Brem et al., J. Neurosurg. 74:441-446 ( 1991 ).
is The dosage of the compound will depend on the condition being treated, the particular compound, and other clinical factors such as weight and condition of the human or animal and the route of administration of the compound. It is to be understood that the present invention has application for both 2o human and veterinary use. For oral administration to humans, a dosage of between approximately 0.1 to 300 mg/kg/day, preferably between approximately 0.5 and 50 mg/kg/day, and most preferably between approximately 1 to 10 mg/kg/day, is generally sufficient.
2s The formulations include those suitable for oral, rectal, ophthalmic, (including intravitreal or intracameral) nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intratracheal, and epidural) administration. The formulations 3o may conveniently be presented in unit dosage form and may be prepared by conventional pharmaceutical techniques. Such techniques include the step of bringing into association the active ingredient and the pharmaceutical carriers) or excipient(s). In general, the formulations are prepared by uniformly and 3s intimately bringing into associate the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
Formulations of the present invention suitable for oral administration may be presented as discrete units such as s capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil emulsion and as a bolus, etc.
io A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, is preservative, surface active or dispersing agent. Molded tablets may be made by molding, in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may be optionally coated or scored and may be formulated so as to provide a slow or controlled release of the active 2o ingredient therein.
Formulations suitable for topical administration in the mouth include lozenges comprising the ingredients in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin zs and glycerin, or sucrose and acacia; and mouthwashes comprising the ingredient to be administered in a suitable liquid carrier.
Formulations suitable for topical administration to the skin may be presented as ointments, creams, gels and pastes comprising the ingredient to be administered in a pharmaceutical 3o acceptable carrier. A preferred topical delivery system is a transdermal patch containing the ingredient to be administered.
Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
Formulations suitable for nasal administration, wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of 20 to 500 microns which is administered in the manner in which snuff is s administered, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
Suitable formulations, wherein the carrier is a liquid, for administration, as for example, a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient.
io Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
Formulations suitable for parenteral administration is include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The 2o formulations may be presented in unit-dose or mufti-dose containers, for example, sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) conditions requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous injection 2s solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
Preferred unit dosage formulations are those containing a daily dose or unit, daily suti-dose, as herein above recited, or an appropriate fraction thereof, of the administered 3o ingredient.
It should be understood that ~ in addition to the ingredients, particularly mentioned above, the formulations of the present invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include flavoring agents.
Diseases associated with corneal neovascularization that can be treated according to the present invention include but s are not limited to, diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma and retrolental fibroplasia, epidemic keratoconjunctivitis, Vitamin A
deficiency, contact lens overwear, atopic keratitis, superior limbic keratitis, pterygium keratitis sicca, sjogrens, acne rosacea, io phylectenulosis, syphilis, Mycobacteria infections, lipid degeneration, chemical burns, bacterial ulcers, fungal ulcers, Herpes simplex infections, Herpes zoster infections, protozoan infections, Kaposi sarcoma, Mooren ulcer, Terrien's marginal degeneration, mariginal keratolysis, trauma, rheumatoid arthritis, is systemic lupus, polyarteritis> Wegeners sarcoidosis, Scleritis, Steven's Johnson disease, periphigoid radial keratotomy, and corneal graph rejection.
Diseases associated with retinal/choroidal neovascularization that can be treated according to the present 2o invention include, but are not limited to, diabetic retinopathy, macular degeneration, sickle cell anemia, sarcoid, syphilis.
pseudoxanthoma elasticum, Pagets disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis, mycobacterial infections, Lyme's disease, systemic lupus 25 erythematosis, retinopathy of prematurity, Eales disease, Bechets disease, infections causing a retinitis or choroiditis, presumed ocular histoplasmosis, Bests disease, myopia, optic pits, Stargarts disease, pars planitis, chronic retinal detachment, hyperviscosity syndromes, toxoplasmosis, trauma and post-laser complications.
3o Other diseases include, but are not limited to, diseases associated with rubeosis (neovasculariation of the angle) and diseases caused by the abnormal proliferation of fibrovascular or fibrous tissue including all forms of proliferative vitreoretinopathy, whether or not associated with diabetes.
Another disease which can be treated according to the present invention is rheumatoid arthritis. It is believed that the blood vessels in the synovial lining of the joints undergo angiogenesis. In addition to forming new vascular networks, the endothelial cells release factors and reactive oxygen species that lead to pannus growth and cartilage destruction.
The factors involved in angiogenesis may actively contribute to and help maintain, the chronically inflamed state of rheutnatoid arthritis.
Another disease that can be treated according to the present invention are hemangiomas, Osler-Weber-Rendu disease, or hereditary hemorrhagic telangiectasia, solid or blood borne tumors and acquired immune deficiency syndrome.
This invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications and equivalents thereof which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the present invention andlor the scope of the appended claims.
Example I
The chick embryo chorioallantoic membrane assay described by Crum et al, Science 230:1375 et seq. ( 1985), is used to identify compounds that do not require further metabolic conversion. See also, U.S. Patent 5,001,116, which describes the CAM
assay at col.
It should be noted that angiogenesis has been associated with blood-born tumors such as leukemias, any of various acute or chronic neoplastic diseases of the bone marrow is in which unrestrained proliferation of white blood cells occurs, usually accompanied by anemia, impaired blood clotting, and enlargement of the lymph nodes, Iiver, and spleen. It is believed that angiogenesis plays a role in the abnormalities in the bone marrow that give rise to leukemia-like tumors.
2o Angiogenesis is important in two stages of tumor metastasis. The first stage where angiogenesis stimulation is important is in the vascularization of the tumor which allows tumor cells to enter the blood stream and to circulate throughout the body. After the tumor cells have left the primary site, and zs have settled into the secondary, metastasis site, angiogenesis must occur before the new tumor can grow and expand. Therefore, prevention of angiogenesis could lead to the prevention of metastasis of tumors and possibly contain the neoplastic growth at the primary site.
3o Knowledge of the role of angiogenesis in the maintenance and metastasis of tumors has led to a prognostic indicator for breast cancer. The amount of neovascularization found in the primary tumor was determined by counting the microvessel density in the area of the most intense 3s neovascularization in invasive breast carcinoma. A high level of microvessel density was found to correlate with tumor recurrence. Control of angiogenesis by therapeutic means could possibly lead to cessation of the recurrence of the tumors.
Angiogenesis is also involved in normal physiological s processes such as reproduction and wound healing. Angiogenesis is an important step in ovulation and also in implantation of the blastula after fertilization. Prevention of angiogenesis could be used to induce amenorrhea, to block ovulation or to prevent implantation by the blastula.
io In wound healing, excessive repair or fibroplasia can be a detrimental side effect of surgical procedures and may be caused or exacerbated by angiogenesis. Adhesions are a frequent complication of surgery and lead to problems such as small bowel obstruction.
is Several kinds of compounds have been used to prevent angiogenesis. Taylor et al. have used protamine to inhibit angiogenesis, see Taylor et al., Nature 297:307 (1982). The toxicity of protamine limits its practical use as a therapeutic.
Folkman et a1. have disclosed the use of heparin and steroids to 2o control angiogenesis. See Folkman et al., Science 221:719 ( 1983) and U.S. Patent Nos. 5,001,116 and 4,994,443. Steroids, such as tetrahydrocortisol, which lack gluco and mineral corticoid activity, have been found to be angiogenic inhibitors.
Other factors found endogenously in animals, such as 2s a 4 kDa glycoprotein from bovine vitreous humor and a cartilage derived factor, have been used to inhibit angiogenesis. Cellular factors such as interferon inhibit angiogenesis. For example, interferon a or human interferon Q has been shown to inhibit tumor-induced angiogenesis in mouse dermis stimulated by 3o human neoplastic cells. Interferon Li is also a potent inhibitor of angiogenesis induced by allogeneic spleen cells. See Sidky et al., Cancer Research 47:5155-5161 (1987). Human recombinant a interferon (alpha/A) was reported to be successfully used in the treatment of pulmonary hemangiomatosis, an angiogenesis-induced disease. See White et al., New England J. Med.
320:1197-1200 ( 1989).
Other agents which have been used to inhibit angiogenesis include ascorbic acid ethers and related compounds.
s See Japanese Kokai Tokkyo Koho No. 58-131978. Sulfated polysaccharide DS 4152 also shows angiogenic inhibition. See Japanese Kokai Tokkyo Koho No. 63-119500. A fungal product.
fumagillin, is a potent angiostatic agent in vitro. The compound is toxic in vivo, but a synthetic derivative, AGM 12470, has been io used in vivo to treat collagen II arthritis. Fumagillin and O-substituted fumagillin derivatives are disclosed in EPO
Publication Nos. 0325199A2 and 0357061 A 1.
PCT Application No. WO 92/14455 to Kaplan et al.
is directed to a method for controlling abnormal concentration of is TNF-a by administering thalidomide or thalidomide derivatives to a patient with toxic concentrations of TNF-a.
The above compounds are either topical or injectable therapeutics. Therefore, there are drawbacks to their use as a general angiogenic inhibitor and lack adequate potency. For 2o example, in prevention of excessive wound healing, surgery on internal body organs involves incisions in various structures contained within the body cavities. These wounds are not accessible to local applications of angiogenic inhibitors. Local delivery systems also involve frequent dressings which are 2s impracticable for internal wounds, and increase the risk of infection or damage to delicate granulation tissue for surface wounds.
Thus, a method and composition are needed that are capable of inhibiting angiogenesis and which are easily 3o administered. A simple and efficacious method of treatment would be through the oral route. If an angiogenic inhibitor could be given by an oral route, the many kinds of diseases discussed above,' and other angiogenic dependent pathologies, could be treated easily. The optimal dosage could be distributed in a form 3s that the patient could self-administer.
_8_ Sl~Bty 0f tjlC lilieilt1011 In accordance with the preset invention, compositions and mahods are provided that are effecxive in inhibiting unwanted aqgiogenesis. These compositions are easily administered by different routes including oral and can be given in dosages that are safe and provide angiogenic inhibition at internal sites. The present invention provides a method of treating mammalian diseases mediated by undesired and uncontrolled angiogenesis by administering a composition comprising an anti-angiogenic compound in a dosage sufficient to inhibit angiogenesis.
The present invention also includes angiogenic inhibiting compounds that contain an epoxide group. These angiogenic inhibiting compounds can be administered to a human or animal alone or with epoxide hydrolase inhibiting .
The present invention is especially useful for treating cxrtain ocular neovascular diseases such as macular degeneration. The compounds which are contemplated as part of the present invention preferably can be given orally to the patient and thereby halt the progression of the disease. Other diseases that can be treated using the present invention are diabetic retinopathy, neovascular glaucoma and retrolental fibroplasia.
Accordingly, the present invention in one aspect seeks to provide a compound a~xl the use thereof to inhibit unwanted angiogeaesis in a human or animal.
the present invention seeks to provide a composition for inhibiting angiogenesis by oral administration of the composition.
Further still the present invention seeks to provide a treatment for disease's mediatod by angiogenesis.
Still further the present invention soaks to provide a treatment for ~cttlar degeneration.
Yet another aspect of the present invention seeks to provide a treatmenx for all forma of proliferative vitreoretinopathy including those forms not associated with diabetes.
Further again the present invention seeks to provide a treatme~ for solid tumors.
Still further the present invention seeks to provide a composition and use thereof for the treatment of blood-born tumors such as leukemia.
It is another object of the present invention to provide a composition and use thereof for the treatment of hemangioma., It is another object of the present invention to provide a composition and use thereof for the treatment of retrolental fibroplasia.
It is another object of the present invention to provide a composition and use thereof for the treatment of psoriasis.
It is another object of the presetrt invention to provide a composition and use . thereof for the treatment of Kaposi's sarcoma.
It is another object of the present invention to provide a composition and use thereof for the treatment of Crohn's diseases.
It is another object of the present invention to provide a method and composition for the treatment of diabetic retinopathy.
The invention to which the claims herein are directed is to the use of thalidomide for the treatment of angioge~sis or unwanted angiogenesis or for the inhibiting or preventing angiogenesis.
Further the invention contemplates the use of thalidomide in the manufacture of a medicament for the treatment of an undesired angiogenesis, umvanted angiogenesis, the inhibiting of angiogenesis or the prevention of angiogenesis.
Other features and advantages of the invention will be apparent from the following description of preferred embodiments thereof.
These and other aspects, features and advantages of the present invention will becott~e apparent after a review of the following detailed description of the disclosed embodiments and the appended claims.
Brief Description of the Figures Figures 1 through 3 are a listing of representative compounds in the genus represented by the following general formulas:
s A) R' Rs ~R
R3 ,/Rg R9 Rs B) R' 1 Rs \R8-R9 Ra C) R
js R Re_R9 Ra to Figure 4 is a listing of representative compounds in the genus represented by the following general formula:
O
R''Z ~N-'R2a is Figure 5 is a listing of representative compounds in the genus represented by the following general formula:
O~C~OHO
i-X
H
Figure 6 shows the effect of thalidomide and EM 12 on angiogenesis in a rabbit cornea model of angiogenesis.
Figure 7 shows the effect of thalidomide on the area s of corneal vascularization in a rabbit cornea model of angiogenesis.
Detailed Description The present invention includes compositions and io methods for the treatment of diseases that are mediated by angiogenesis. One embodiment of the present invention is the use of thalidomide or the metabolites of thalidomide as disclosed herein to inhibit unwanted angiogenesis. The present invention _ also includes compounds which cause dysmelia is the developing is fetus and have anti-angiogenic activity. The present invention comprises a method of treating undesired angiogenesis in a human or animal comprising the steps of administering to the human or animal with the undesired angiogenesis a composition comprising an effective amount of a teratogenic compound that is anti 2o angiogenic.
Compounds that can be used in accordance with the present invention include compounds included in the following general formulae. Examples of compounds that have anti-angiogenic properties having one of the following three 2s formulae (A), (B), or (C):
A) R~ 1 Rs ~R
R3 /Rg- R9 Ra B) R i Rs RQ
C) R i Rs R 'Rs _ R9 Ra In the above formulae A), B), and C), R1, R2, R3 and R.~ can be selected from: -H; -OH; =O, straight chained and branched alkanes, alkenes, alkynes; cyclic alkanes, alkenes, and alkynes;
io combinations of cyclic and acyclic alkanes, alkenes, and alkynes;
alcohol, aldehyde, ketone, carboxylic acid, ester, or ether moieties in combination with acyclic, cyclic, or combination acyclic/cyclic moieties; aza; amino; -XOn or -O-XOn, (where X=N and n=2; X=S and n=2 or 3; or X=P and n=1-3]; and is halogens; R5, R(, R7, and Rg are each independently selected from:
-C-Rio: 'N-Rto:
or -O- where Y is optional and is the same as defined above for R l ; and R 1 p is the same as defined above for R l , or (where Y is absent) R 1 p is =O; and R9 is a moiety having formula D), E), F), G) or H):
D) F) ~t~-Rts -Rtt-Rt2 -R11/ Rta Rta'_'Rm Rtb Rts s E) G) ~Rt3 Rt2 W
R~~
~Rtz-Rta -RR
Rtt l tt \ ~ 'Rts Rt3-Rts R1~~Rtb where each of Rl 1 - R17 is (independently) the same as defined above for R5;
io I~
Rt8 -C-Rt9 i Rio where R 1 g, R 19 and R2p are, independently selected from ° ° q q -H, CH3, -C-OH,-C-NH2.-(CHZ),~ C-OH, or-(CH2)"-C-NH,, is and n=1 to 4.
Accordingly, another aspect of the present invention features inhibiting angiogenesis in a mammal by administering a therapeutic composition comprising one of the above-described compounds in a dosage sufficient to inhibit angiogenesis In preferred embodiments, the compound has formula B), where RS and R( are selected from the group consisting of:
-CHI , -CHOH, and~CO
s and R9 has formula F) or H); and R14 and RI6 are selected from the group consisting of:
R, I
;CH2, ;CHOH, or- ~-;and Rls and is -O-, or-N-, O
where R21 is -H, -CH3, or -OH. Specific preferred compounds according to this aspect of the present invention include io thalidomide, its precursors, metabolites and analogs. Particular analogs include EM-12, N-phthaloyl-DL-glutamic acid (PGA) or N-phthaloyl-DL-glutamine anhydride. Examples of compounds that are members of this genus are listed in Figures 1 through 3.
It is to be understood that the compounds included as part of the is present invention are not to be limited to those compounds shown in Figures 1 through 3 and include all other compounds that are members of the genus described by the general formulas herein.
Compounds of the following formula that have anti-angiogenic properties:
O
R2' \ \N-R2a \v 2s where R22 and R23 are (independently), -H, -F, -C1, -Br, -I, -CH3, or -CH2 -CH3; and R24 is -H, -CH3, or -CH2 -CH3.
The present invention also features inhibiting angiogenesis in a mammal by administering a compound according to the above formulae in a dosage sufficient to inhibit angiogenesis. Examples of specific compounds that are members of this genus are listed in Figure 4.
Angiogenesis inhibition hydrolysis products of thalidomide having the following general formula can be used in practicing the present invention:
~O~ ,OH
I
H
where X is R6 as defined above, or -X
O I O
X is R25-C-C-(CH2)n-C-R26 io and R25 and R26 are, independently, -OH, -H, or NH2, and n=1 through 4. Examples of such compounds are shown in l figure 5.
Angiogenesis inhibition compounds having the following general formula can be used in practicing the present invention:
(I) O O R" (II) I
R' / N
/N O
O ( O \ X
~ (a) CH,-N O
wherein compounds of structure (I), wherein R is selected from the group consisting of hydrogen, alkyl radicals of 1 to 6 carbon atoms, the phenyl radical, and the benzyl radical;
2o and wherein R' is selected from the group consisting of the phthalimido radical and the succinimido radical and of structure (II), wherein X is CH2 or C=O; R" is H, -CH2CH3, -C6H5, -CH2C6H5, -CH2CH=CH2, or (a) and hydrolysis products of the compounds wherein R" is H and the piperidino ring or both the 2s piperidino and the imido ring are hydrolyzed.
1.
Another set of compounds that are considered part of the present invention are the epoxides of thalidomide, EM-12 and EM-138. Representative epoxide compounds are shown as follows:
O ~ C
i CN O I N O
\ Cr N; O C N\
O O H O O H
Epoxides of thalidomide O O O
C
\ ~ ~N ~O I N N~O
O NH O O H
to Epoxides of EM 12 O O
I II
O o ~~OH ~ C~OH
C \ Cv I N I _N
\ 1 _-_O O I =O
OH OH
Epoxides of EM 138 It should be understood that the epoxide can be attached at the 6,1 site on the benzene ring, the 1,2 site, the 2,3 site 3,4 or the 4,S site. All of these compounds are contemplated as part of the present invention.
2o The epoxides of the thalidomide, EM-12, and EM 138 can be hydrolized to the following compounds:
_I7_ O O
HO / I ~ HO
N O ~ N ~O
\ C N HO
C N
O O H O O H
O O
HO / C~ HO
N ~O ~ N ~O
N HO \ N
O/ H O~ H
O
OH
O
HO / C HO / C N
HO \ I OH
O
to It is to be understood that the hydroxyl group can be on carbons I, 2, 3, 4, 5 and 6 of the benzene ring. Also contemplated as part of the present invention are dihydroxyl compounds wherein the two hydroxyl groups are located bis to each other on carbons 1, 2, 3, 5 and 6 of the above compounds.
i5 The epoxides, the hydrolysis products of the epoxides, and the hydrolysis products of the thalidomide are alI contemplated to be part of the present invention.
It is known that epoxides are hydrolized by a group . of enzymes known as epoxide hydrolases. There is a class of 2o compounds which are epoxide hydrolase inhibitors. Examples of these compounds are valpromide (2-propylpentanamide) and valproic acid (2-propylpentanoic acid). Because epoxides are - l8-important angiogenesis inhibitors, it is contemplated as part of the present invention, compositions comprising any of the angiogenesis inhibitors compounds recited herein in combination with epoxide hydrolase inhibitors. The epoxide hydrolase s inhibitors can be administered to a human or animal together or sequentially. The expoxide group appears to be an important substituent common to several angiogenesis inhibitors. The use of epoxide hydrolase inhibitors to potentiate the activity of any angiogenesis inhibitor containing an epoxide is contemplated as to part of the present invention. For example, the epoxide hydrolase inhibitors can be administered with the following epoxide-containing anti-angiogenesis compounds: AGM 1470, Eponimycin, microbial metabolites of Scolecobasidium arenarium designated f/2015, fr/111142 and fr/18487. See Oikawa, is Biochem Biophys. Res. Comm, Vol. 81:1070 (1971) and Otsuka, J. Microbial. Biotech., Vol 1:163 (1991).
It is contemplated as an embodiment of the present invention the use of the epoxide containing angiogenesis inhibitors with or without epoxide hydrolase inhibitors as a treatment for zo diseases mediated by elevated or toxic levels of TNF-a. TNF-a has been recognized as manifesting a dose dependent toxicity. If present at low levels for a long period of time, TNF-a can result in cachexia. Cachexia is a general weight loss and wasting occurring in the course of some chronic diseases such as cancer, 2s opportunistic infections of AIDS, inflammatory diseases, parasitic diseases, tuberculosis, and high dose IL-2 therapy. The epoxide containing angiogenesis inhibitors, with or without epoxide hydrolase inhibitors, are also effective in treating diseases such as septic shock, leprosy and graph vs. host disease.
3o Other embodiments are within the present invention.
For example, other dysmelia-causing compounds can be used according to the present invention, e.g. 4-methylphthalic acid, pyridoxine, vasopressin, acetazolamide, or a compound having the following formula (where R= H, -OH, or -CH3):
O
I
R
Other compounds which are teratogens, such as valproic acid (2-propylpentanoic acid), the retinoids, such as cis-retinoic acid, and rifampin may also be used in accordance with the invention.
s In summary, the preferred compounds are thalidomide, as well as analogs, hydrolysis products, metabolites and precursors of thalidomide that are teratogenic, and, more specifically, that cause dismelia. However, it is to be understood that it is not necessary for a compound to have both teratogenic io activity and angiogenesis inhibiting activity to be considered part of the present invention. Dysmelia-causing compounds can be identified by the general procedures of Helm, Ar:,neimittle-forschung. 31(i/6):941-949 (1981), in which rabbit pups are examined after exposure to the compound in utero. The is compounds can generally be purchased, e.g., from Andrulis Pharmaceuticals, Beltsville, MD, or synthesized according to known procedures. It is to be understood that the compounds of the present invention can exist as enantiomers and that the racemic mixture of enantiomers or the isolated enantiomers are 2o all considered as within the scope of the present invention.
Many of the compounds that are contemplated as part of the present invention can be enriched in optically active enantiomers of the compounds specified above. Specifically, Blaschke has reported that the S enanantiomers may be ~s disproportionately responsible for the dismelia-producing effect of these compounds. See, generally Blaschke, Ar~neimittelforschung 29:1640-1642 (1979). The above described articles generally describe procedures to obtain optically active preparations of the compounds of interest. See.
3o e.g. Shealy et al., Chem. Indus. 1030 ( 1965); and Casini et al., Farmaco Ed. Sci. 19:563 ( 1964). v The compounds described above can be provided as pharmaceutically acceptable formulations using formulation methods known to those of ordinary skill in the art. These s formulations can be administered by standard routes. In general, the combinations may be administered by the topical.
transdermal, oral, rectal or parenteral (e.g., intravenous, subcutaneous or intramuscular) route. In addition, the combinations may be incorporated into biodegradable polymers io allowing for sustained release of the compound, the polymers being implanted in the vicinity of where drug delivery is desired, for example, at the site of a tumor. The biodegradable polymers and their use are described, for example, in detail in Brem et al., J. Neurosurg. 74:441-446 ( 1991 ).
is The dosage of the compound will depend on the condition being treated, the particular compound, and other clinical factors such as weight and condition of the human or animal and the route of administration of the compound. It is to be understood that the present invention has application for both 2o human and veterinary use. For oral administration to humans, a dosage of between approximately 0.1 to 300 mg/kg/day, preferably between approximately 0.5 and 50 mg/kg/day, and most preferably between approximately 1 to 10 mg/kg/day, is generally sufficient.
2s The formulations include those suitable for oral, rectal, ophthalmic, (including intravitreal or intracameral) nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intratracheal, and epidural) administration. The formulations 3o may conveniently be presented in unit dosage form and may be prepared by conventional pharmaceutical techniques. Such techniques include the step of bringing into association the active ingredient and the pharmaceutical carriers) or excipient(s). In general, the formulations are prepared by uniformly and 3s intimately bringing into associate the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
Formulations of the present invention suitable for oral administration may be presented as discrete units such as s capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil emulsion and as a bolus, etc.
io A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, is preservative, surface active or dispersing agent. Molded tablets may be made by molding, in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may be optionally coated or scored and may be formulated so as to provide a slow or controlled release of the active 2o ingredient therein.
Formulations suitable for topical administration in the mouth include lozenges comprising the ingredients in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin zs and glycerin, or sucrose and acacia; and mouthwashes comprising the ingredient to be administered in a suitable liquid carrier.
Formulations suitable for topical administration to the skin may be presented as ointments, creams, gels and pastes comprising the ingredient to be administered in a pharmaceutical 3o acceptable carrier. A preferred topical delivery system is a transdermal patch containing the ingredient to be administered.
Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
Formulations suitable for nasal administration, wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of 20 to 500 microns which is administered in the manner in which snuff is s administered, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
Suitable formulations, wherein the carrier is a liquid, for administration, as for example, a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient.
io Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
Formulations suitable for parenteral administration is include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The 2o formulations may be presented in unit-dose or mufti-dose containers, for example, sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) conditions requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous injection 2s solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
Preferred unit dosage formulations are those containing a daily dose or unit, daily suti-dose, as herein above recited, or an appropriate fraction thereof, of the administered 3o ingredient.
It should be understood that ~ in addition to the ingredients, particularly mentioned above, the formulations of the present invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include flavoring agents.
Diseases associated with corneal neovascularization that can be treated according to the present invention include but s are not limited to, diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma and retrolental fibroplasia, epidemic keratoconjunctivitis, Vitamin A
deficiency, contact lens overwear, atopic keratitis, superior limbic keratitis, pterygium keratitis sicca, sjogrens, acne rosacea, io phylectenulosis, syphilis, Mycobacteria infections, lipid degeneration, chemical burns, bacterial ulcers, fungal ulcers, Herpes simplex infections, Herpes zoster infections, protozoan infections, Kaposi sarcoma, Mooren ulcer, Terrien's marginal degeneration, mariginal keratolysis, trauma, rheumatoid arthritis, is systemic lupus, polyarteritis> Wegeners sarcoidosis, Scleritis, Steven's Johnson disease, periphigoid radial keratotomy, and corneal graph rejection.
Diseases associated with retinal/choroidal neovascularization that can be treated according to the present 2o invention include, but are not limited to, diabetic retinopathy, macular degeneration, sickle cell anemia, sarcoid, syphilis.
pseudoxanthoma elasticum, Pagets disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis, mycobacterial infections, Lyme's disease, systemic lupus 25 erythematosis, retinopathy of prematurity, Eales disease, Bechets disease, infections causing a retinitis or choroiditis, presumed ocular histoplasmosis, Bests disease, myopia, optic pits, Stargarts disease, pars planitis, chronic retinal detachment, hyperviscosity syndromes, toxoplasmosis, trauma and post-laser complications.
3o Other diseases include, but are not limited to, diseases associated with rubeosis (neovasculariation of the angle) and diseases caused by the abnormal proliferation of fibrovascular or fibrous tissue including all forms of proliferative vitreoretinopathy, whether or not associated with diabetes.
Another disease which can be treated according to the present invention is rheumatoid arthritis. It is believed that the blood vessels in the synovial lining of the joints undergo angiogenesis. In addition to forming new vascular networks, the endothelial cells release factors and reactive oxygen species that lead to pannus growth and cartilage destruction.
The factors involved in angiogenesis may actively contribute to and help maintain, the chronically inflamed state of rheutnatoid arthritis.
Another disease that can be treated according to the present invention are hemangiomas, Osler-Weber-Rendu disease, or hereditary hemorrhagic telangiectasia, solid or blood borne tumors and acquired immune deficiency syndrome.
This invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications and equivalents thereof which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the present invention andlor the scope of the appended claims.
Example I
The chick embryo chorioallantoic membrane assay described by Crum et al, Science 230:1375 et seq. ( 1985), is used to identify compounds that do not require further metabolic conversion. See also, U.S. Patent 5,001,116, which describes the CAM
assay at col.
7 of the patent. Briefly, fertilized chick embryos are removed from their shell on day 3 or 4 and a methylcellulose disc containing the compound is implanted on the chorioallantoic membrane. The embryos are examined 48 hours later and if a clear avascular zone appears around the methylcellulose disc, the diameter of that zone is measured.
Example II
Rabbit cornea angiogenesis assay Pellets for implantation into rabbit corneas were made by mixing 110 ~tl of saline containing 12 ~tg of recombinant s bFGF (Takeda Pharmaceuticals-Japan) with 40 mg of sucralfate (Bukh Meditec-Denmark); this suspension was added to 80 ~1 of 12% hydron (Interferon Sciences) in ethanol. 10 ~tl aliquots of this mixture was then pipetted onto teflon pegs and allowed to dry producing approximately 17 pellets. A pellet was implanted into io corneal micropockets of each eye of an anesthetized female New Zealand white rabbit, 2mm from the Iimbus followed by topical application of erythromycin ointment onto the surface of the cornea. The animals were fed daily from 2 days post-implantation by gastric lavage with either drug suspended in 0.5%
is carboxymethyl cellulose or 0.5% carboxymethyl cellulose alone.
Thalidomide was purchased from Andruius Pharmaceutical (Maryland) and the EM-12 and Supidimide were kindly provided by Grunenthal GMBH (Germany). The animals were examined with a slit lamp every other day in a masked manner by the same zo corneal specialist. The area of corneas neovascularization was determined by measuring with a reticule the vessel length (L) from the limbus and the number of clock hours (C) of limbus involved. A fotmuia was used to determine the area of a circular band segment: C/12 * 3.1416 [r2-(r-L)2] where r=6 mm the 2s measured radius of the rabbit cornea. Various mathematical models were utilized to determine the amount of vascularized cornea and this formula was found to provide the most accurate approximation of the area of the band of neovascularization that grows towards the pellet.
3o It is important to note that the rabbit cornea assay is preferable because it will generally recognize compounds that are inactive per se but are metabolized to yield active compounds.
Thalidomide related compounds, as shown below in Example III.
are known to be teratogens and are candidates for use in the 3s present invention.
Example III
Inhibition of bFGF induced corneal neovasculari~ation by thalidomide and related analog expressed as percent of median s control on day 8 Pellets containing bFGF and sucralfate were implanted into micropockets of both corneas of rabbits according to Example II. Vessel ingrowth into clear cornea from the limbus was first noted on day 2 and treatments (200 mg/kg orally) were io begun on this day. The area of corneal neovascularization was measured from day 4 through day 12. Day 8 measurements were used for comparison between groups. No regression of vessels and near maximal neovascularization was seen at this time point.
Statistical analysis was performed with ANOVA with ranked data Zs to account for interexperimental variation and to guard against a non-normal distribution of data (i.e. outliers) by utilizing a nonparametric method.
The compounds tested were as follows:
O
II
C
N ~O
'C N
Zo O O H
thalidomide o II
C~
N ~O
N
O H
-z7-LL
c N ~O
'C O
I I
O O
phthaloyl glutamic anhydride (PGA) O
OH
O
~N
OH
O O
s phthaloyl glutamic acid (PG Acid) O
II
C
N ~O
~S02 N
O H
supidimide.
Treatment with a dose of (200 mg/kg) of thalidomide resulted in an inhibition of the area of vascularized cornea that io ranged from 30-51 % in three experiments with a median inhibition of 36% (Figure 6) (n=30 eyes, p=0.0001, 2 way ANOVA with ranked data). The inhibition of angiogenesis by thalidomide was seen after only two doses (Figure 7). The rabbits did not demonstrate obvious sedation and there were no signs of is toxicity or weight loss. The teratogenic analog EM-12, which shares the other properties of thalidomide was also inhibitory, with a median inhibition of 42% (n=10 eyes, p=0.002, 1-way ANOVA with ranked data). Supidimide, a nonteratogenic analog of thalidomide that retains the sedative properties of thalidomide, 2o exhibited no activity (area 107% of control, n=IO eyes, not statistically different from control). Other analogs, PGA and PG
acid displayed weaker inhibitory effects than thalidomide (data _2g_ not shown). The density of vessel ingrowth in thalidomide-treated animals was also markedly reduced.
Example IV
s EM-12 in rabbit cornea assay EM-12 was tested in the rabbit cornea assay described in Example II at 100 mg/kg/day and showed 21 %
inhibition, and at 200mg/kg/day the assay showed 43% inhibition.
io Example V
Phthaloyl glutamic acid in CAM
Phthaloyl glutamic acid was tested in the above described CAM assay and exhibit an avascular zone with a mild scar.
is Example VI
Phthaloyl glutamic acid in rabbit cornea assay Phthaloyl glutamic acid described above at 200 mg/kg and exhibited 29% inhibition of angiogenesis.
Zo Example VII
Phthaloyl glutamic anhydride in CAM assay Phthaloyl glutamic anhydride was test in the CAM
assay described above and exhibited an avascular zone.
It should be understood, of course, that the foregoing 2s relates only to preferred embodiments of the present invention and that numerous modifications or alterations may be made therein without departing from the spirit and the scope of the invention as set forth in the appended claims.
Example II
Rabbit cornea angiogenesis assay Pellets for implantation into rabbit corneas were made by mixing 110 ~tl of saline containing 12 ~tg of recombinant s bFGF (Takeda Pharmaceuticals-Japan) with 40 mg of sucralfate (Bukh Meditec-Denmark); this suspension was added to 80 ~1 of 12% hydron (Interferon Sciences) in ethanol. 10 ~tl aliquots of this mixture was then pipetted onto teflon pegs and allowed to dry producing approximately 17 pellets. A pellet was implanted into io corneal micropockets of each eye of an anesthetized female New Zealand white rabbit, 2mm from the Iimbus followed by topical application of erythromycin ointment onto the surface of the cornea. The animals were fed daily from 2 days post-implantation by gastric lavage with either drug suspended in 0.5%
is carboxymethyl cellulose or 0.5% carboxymethyl cellulose alone.
Thalidomide was purchased from Andruius Pharmaceutical (Maryland) and the EM-12 and Supidimide were kindly provided by Grunenthal GMBH (Germany). The animals were examined with a slit lamp every other day in a masked manner by the same zo corneal specialist. The area of corneas neovascularization was determined by measuring with a reticule the vessel length (L) from the limbus and the number of clock hours (C) of limbus involved. A fotmuia was used to determine the area of a circular band segment: C/12 * 3.1416 [r2-(r-L)2] where r=6 mm the 2s measured radius of the rabbit cornea. Various mathematical models were utilized to determine the amount of vascularized cornea and this formula was found to provide the most accurate approximation of the area of the band of neovascularization that grows towards the pellet.
3o It is important to note that the rabbit cornea assay is preferable because it will generally recognize compounds that are inactive per se but are metabolized to yield active compounds.
Thalidomide related compounds, as shown below in Example III.
are known to be teratogens and are candidates for use in the 3s present invention.
Example III
Inhibition of bFGF induced corneal neovasculari~ation by thalidomide and related analog expressed as percent of median s control on day 8 Pellets containing bFGF and sucralfate were implanted into micropockets of both corneas of rabbits according to Example II. Vessel ingrowth into clear cornea from the limbus was first noted on day 2 and treatments (200 mg/kg orally) were io begun on this day. The area of corneal neovascularization was measured from day 4 through day 12. Day 8 measurements were used for comparison between groups. No regression of vessels and near maximal neovascularization was seen at this time point.
Statistical analysis was performed with ANOVA with ranked data Zs to account for interexperimental variation and to guard against a non-normal distribution of data (i.e. outliers) by utilizing a nonparametric method.
The compounds tested were as follows:
O
II
C
N ~O
'C N
Zo O O H
thalidomide o II
C~
N ~O
N
O H
-z7-LL
c N ~O
'C O
I I
O O
phthaloyl glutamic anhydride (PGA) O
OH
O
~N
OH
O O
s phthaloyl glutamic acid (PG Acid) O
II
C
N ~O
~S02 N
O H
supidimide.
Treatment with a dose of (200 mg/kg) of thalidomide resulted in an inhibition of the area of vascularized cornea that io ranged from 30-51 % in three experiments with a median inhibition of 36% (Figure 6) (n=30 eyes, p=0.0001, 2 way ANOVA with ranked data). The inhibition of angiogenesis by thalidomide was seen after only two doses (Figure 7). The rabbits did not demonstrate obvious sedation and there were no signs of is toxicity or weight loss. The teratogenic analog EM-12, which shares the other properties of thalidomide was also inhibitory, with a median inhibition of 42% (n=10 eyes, p=0.002, 1-way ANOVA with ranked data). Supidimide, a nonteratogenic analog of thalidomide that retains the sedative properties of thalidomide, 2o exhibited no activity (area 107% of control, n=IO eyes, not statistically different from control). Other analogs, PGA and PG
acid displayed weaker inhibitory effects than thalidomide (data _2g_ not shown). The density of vessel ingrowth in thalidomide-treated animals was also markedly reduced.
Example IV
s EM-12 in rabbit cornea assay EM-12 was tested in the rabbit cornea assay described in Example II at 100 mg/kg/day and showed 21 %
inhibition, and at 200mg/kg/day the assay showed 43% inhibition.
io Example V
Phthaloyl glutamic acid in CAM
Phthaloyl glutamic acid was tested in the above described CAM assay and exhibit an avascular zone with a mild scar.
is Example VI
Phthaloyl glutamic acid in rabbit cornea assay Phthaloyl glutamic acid described above at 200 mg/kg and exhibited 29% inhibition of angiogenesis.
Zo Example VII
Phthaloyl glutamic anhydride in CAM assay Phthaloyl glutamic anhydride was test in the CAM
assay described above and exhibited an avascular zone.
It should be understood, of course, that the foregoing 2s relates only to preferred embodiments of the present invention and that numerous modifications or alterations may be made therein without departing from the spirit and the scope of the invention as set forth in the appended claims.
Claims (16)
1. ~Use of thalidomide for the treatment of a disease selected from the group consisting of Vitamin A deficiency, contact lens overwear, chemical burns, trauma, radial keatotomy, rubeosis and pemphigoid.
2. ~Use according to claim 1 wherein the disease is Vitamin A deficiency.
3. ~Use according to claim 1 wherein the disease is contact lens overwear.
4. ~Use according to claim 1 wherein the disease is chemical burns.
5. ~Use according to claim 1 wherein the disease is trauma.
6. ~Use according to claim 1 wherein the disease is radial keatotomy.
7. ~Use according to claim 1 wherein the disease is rubeosis.
8. ~Use according to claim 1 wherein the disease is pemphigoid.
9. ~Use of thalidomide in the manufacture of a medicament for the treatment of a disease~
selected from the group consisting of Vitamin A deficiency, contact lens overwear, chemical burns, trauma, radial keatotomy, rubeosis and pemphigoid.
selected from the group consisting of Vitamin A deficiency, contact lens overwear, chemical burns, trauma, radial keatotomy, rubeosis and pemphigoid.
10. ~Use according to claim 9 wherein the disease is Vitamin A deficiency.
11. ~Use according to claim 9 wherein the disease is contact lens overwear.
12. ~Use according to claim 9 wherein the disease is chemical burns.
13. ~Use according to claim 9 wherein the disease is trauma.
14. ~Use according to claim 9 wherein the disease is radial keatotomy.
15. ~Use according to claim 9 wherein the disease is rubeosis.
16. ~Use according to claim 9 wherein the disease is pemphigoid.~
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2504693A | 1993-03-01 | 1993-03-01 | |
| US08/025,046 | 1993-12-15 | ||
| US08/168,817 | 1993-12-15 | ||
| US08/168,817 US5629327A (en) | 1993-03-01 | 1993-12-15 | Methods and compositions for inhibition of angiogenesis |
| CA002157288A CA2157288C (en) | 1993-03-01 | 1994-02-24 | Methods and compositions for inhibition of angiogenesis |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002157288A Division CA2157288C (en) | 1993-03-01 | 1994-02-24 | Methods and compositions for inhibition of angiogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2512926A1 CA2512926A1 (en) | 1994-09-15 |
| CA2512926C true CA2512926C (en) | 2010-08-03 |
Family
ID=26699202
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002157288A Expired - Lifetime CA2157288C (en) | 1993-03-01 | 1994-02-24 | Methods and compositions for inhibition of angiogenesis |
| CA002342974A Expired - Lifetime CA2342974C (en) | 1993-03-01 | 1994-02-24 | Methods and compositions for inhibition of angiogenesis |
| CA2512926A Expired - Lifetime CA2512926C (en) | 1993-03-01 | 1994-02-24 | Methods and compositions for inhibition of angiogenesis |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002157288A Expired - Lifetime CA2157288C (en) | 1993-03-01 | 1994-02-24 | Methods and compositions for inhibition of angiogenesis |
| CA002342974A Expired - Lifetime CA2342974C (en) | 1993-03-01 | 1994-02-24 | Methods and compositions for inhibition of angiogenesis |
Country Status (20)
| Country | Link |
|---|---|
| US (18) | US5629327A (en) |
| EP (4) | EP1245229A3 (en) |
| JP (4) | JPH08507767A (en) |
| KR (1) | KR100506043B1 (en) |
| AT (2) | ATE304356T1 (en) |
| AU (1) | AU676722B2 (en) |
| BR (1) | BR9400764A (en) |
| CA (3) | CA2157288C (en) |
| CO (1) | CO4230017A1 (en) |
| DE (3) | DE69430796T2 (en) |
| DK (2) | DK1264597T3 (en) |
| ES (2) | ES2245711T3 (en) |
| FR (1) | FR08C0036I2 (en) |
| HK (1) | HK1052865A1 (en) |
| LU (1) | LU91471I2 (en) |
| NL (1) | NL300358I2 (en) |
| NZ (4) | NZ262676A (en) |
| PE (1) | PE10095A1 (en) |
| PT (1) | PT688211E (en) |
| WO (1) | WO1994020085A1 (en) |
Families Citing this family (290)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US6228879B1 (en) * | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
| US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US8143283B1 (en) * | 1993-03-01 | 2012-03-27 | The Children's Medical Center Corporation | Methods for treating blood-born tumors with thalidomide |
| US6114355A (en) * | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
| US20040248799A1 (en) * | 1993-05-27 | 2004-12-09 | Holaday John W. | Compositions and methods for treating cancer and hyperproliferative disorders |
| US6805865B1 (en) | 1993-05-27 | 2004-10-19 | Entremed, Inc. | Compositions and methods for treating cancer and hyperproliferative disorders |
| DE4422237A1 (en) * | 1994-06-24 | 1996-01-04 | Gruenenthal Gmbh | Use of lactam compounds as active pharmaceutical ingredients |
| US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
| US6358735B1 (en) | 1995-06-30 | 2002-03-19 | University Of Kansas Medical Center | Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen |
| US6440729B1 (en) | 1995-06-30 | 2002-08-27 | University Of Kansas Medical Center | Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen |
| US6518281B2 (en) * | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
| US6346510B1 (en) | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
| JP3263598B2 (en) * | 1995-11-01 | 2002-03-04 | 有限会社ドット | Bioactive peptide composition for nasal absorption |
| DK2070920T3 (en) * | 1996-07-24 | 2011-06-14 | Celgene Corp | Substituted 2- (2,6-dioxopiperidin-3-yl) phthalimides and 1-oxoisoindolines and method for reducing TNF-α levels |
| HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| EP0925294B3 (en) * | 1996-07-24 | 2018-07-04 | Celgene Corporation | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels |
| US5798368A (en) * | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| US5955496A (en) * | 1996-08-13 | 1999-09-21 | The Regents Of The University Of California | Dihydroxy-oxy-eicosadienoates |
| EP1920773B1 (en) * | 1996-11-05 | 2011-01-05 | The Children's Medical Center Corporation | Thalidomide and dexamethasone for the treatment of tumors |
| US6670337B1 (en) | 1998-01-29 | 2003-12-30 | Yeda Reaearch And Development Co., Ltd. | Facilitation of wound healing with CM101/GBS toxin |
| US6028060A (en) | 1997-01-29 | 2000-02-22 | Vanderbilt University | Treatment of chronic inflammatory diseases with CM101/GBS toxin |
| US5981508A (en) | 1997-01-29 | 1999-11-09 | Vanderbilt University | Facilitation of repair of neural injury with CM101/GBS toxin |
| US5858991A (en) | 1997-01-29 | 1999-01-12 | Vanderbilt University | Facilitation of wound healing with CM101/GBS toxin |
| US6593291B1 (en) | 1997-02-06 | 2003-07-15 | Entremed, Inc. | Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease |
| US5994388A (en) * | 1997-03-18 | 1999-11-30 | The Children's Medical Center Corporation | Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis |
| US6265388B1 (en) | 1997-03-21 | 2001-07-24 | President And Fellows Of Harvard College | Antisense inhibition of angiogenin expression |
| US6174695B1 (en) | 1997-08-12 | 2001-01-16 | The Regents Of The University Of California | Epoxide hydrolase inhibitor methods |
| CA2302017C (en) | 1997-08-25 | 2007-01-30 | Harold Brem | Prevention of adhesions and excessive scar formation using angiogenesis inhibitors |
| US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
| ATE327228T1 (en) * | 1997-11-18 | 2006-06-15 | Celgene Corp | SUBSTITUTED 2-(2,6-DIOXO-3-FLUOROPIPERIDINE-3-YL)-ISOINDOLINES AND THEIR USE FOR REDUCING TNF-ALPHA LEVELS |
| JP4695259B2 (en) * | 1998-03-16 | 2011-06-08 | セルジーン コーポレイション | 2- (2,6-Dioxopiperidin-3-yl) isoindoline derivatives, their preparation and their use as inflammatory cytokine inhibitors |
| US6673828B1 (en) * | 1998-05-11 | 2004-01-06 | Children's Medical Center Corporation | Analogs of 2-Phthalimidinoglutaric acid |
| AU749356B2 (en) * | 1998-05-11 | 2002-06-27 | Children's Medical Center Corporation | Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis |
| AU3980499A (en) | 1998-05-11 | 1999-11-29 | Endowment for Research in Human Biology, Inc., The | Use of neomycin for treating angiogenesis-related diseases |
| US8197430B1 (en) * | 1998-05-22 | 2012-06-12 | Biopheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
| US6620382B1 (en) | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
| US8609614B2 (en) | 1998-07-22 | 2013-12-17 | Vanderbilt University | GBS toxin receptor compositions and methods of use |
| US6576613B1 (en) * | 1998-07-24 | 2003-06-10 | Corvas International, Inc. | Title inhibitors of urokinase |
| US6703050B1 (en) * | 1998-09-04 | 2004-03-09 | The Regents Of The University Of Michigan | Methods and compositions for the prevention or treatment of cancer |
| US6537554B1 (en) | 1998-09-10 | 2003-03-25 | Curagen Corporation | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
| EP1115724A1 (en) * | 1998-09-21 | 2001-07-18 | Shire Biochem Inc. | Quinolizinones as integrin inhibitors |
| US6231889B1 (en) * | 1998-09-21 | 2001-05-15 | Chronorx, Llc | Unit dosage forms for the treatment of herpes simplex |
| US6596690B2 (en) * | 1998-10-06 | 2003-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vasostatin as marrow protectant |
| FR2784580B1 (en) * | 1998-10-16 | 2004-06-25 | Biosepra Inc | POLYVINYL-ALCOHOL MICROSPHERES AND METHODS OF MAKING THE SAME |
| US20030013739A1 (en) * | 1998-12-23 | 2003-01-16 | Pharmacia Corporation | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia |
| US7238711B1 (en) * | 1999-03-17 | 2007-07-03 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
| AU2612100A (en) * | 1999-01-13 | 2000-08-01 | Rockefeller University, The | Methods of promoting or enhancing interleukin-12 production through administration of thalidomide |
| CN1342146A (en) | 1999-03-18 | 2002-03-27 | 塞尔基因公司 | Substituted 1-oxo-and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels |
| PT1040838E (en) * | 1999-03-31 | 2003-08-29 | Gruenenthal Gmbh | AQUOSA SOLUTION OF 3- (1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL) PIPERIDINE-2,6-DIONA |
| US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| US6468990B1 (en) * | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| US6673843B2 (en) * | 1999-06-30 | 2004-01-06 | Emory University | Curcumin and curcuminoid inhibition of angiogenesis |
| US6916843B1 (en) * | 1999-08-11 | 2005-07-12 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-inflammatory actions of cytochrome P450 expoxygenase-derived eicosanoids |
| US7087592B1 (en) | 1999-08-23 | 2006-08-08 | Entre Med, Inc. | Compositions comprising purified 2-methoxyestradiol and methods of producing same |
| US20040214783A1 (en) | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| DE60043156D1 (en) | 1999-11-10 | 2009-11-26 | Biopheresis Technologies Inc | METHOD AND SYSTEM FOR REMOVING CYTOKININ HIBITORS IN PATIENTS |
| US6204270B1 (en) * | 1999-11-12 | 2001-03-20 | Eyal S. Ron | Ophthalmic and mucosal preparations |
| RU2002113076A (en) | 1999-11-18 | 2004-03-10 | Корвас Интернэшнл, Инк. (Us) | Nucleic acids encoding endotheliases, endotheliases and their use |
| US6379708B1 (en) * | 1999-11-20 | 2002-04-30 | Cytologic, Llc | Method for enhancing immune responses in mammals |
| WO2001041755A2 (en) * | 1999-12-02 | 2001-06-14 | The Regents Of The University Of Michigan | Topical compositions comprising thalidomide for the treatment of inflammatory diseases |
| US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| US6699899B1 (en) * | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
| US7700341B2 (en) | 2000-02-03 | 2010-04-20 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| CN1121218C (en) * | 2000-03-08 | 2003-09-17 | 台湾东洋药品工业股份有限公司 | Medicine composition for treating hepatocellular carcinoma |
| JP2003528130A (en) * | 2000-03-24 | 2003-09-24 | バイオスフィアー メディカル，インク． | Microspheres for active embolization |
| US20030212022A1 (en) * | 2001-03-23 | 2003-11-13 | Jean-Marie Vogel | Compositions and methods for gene therapy |
| KR20030003708A (en) * | 2000-03-31 | 2003-01-10 | 셀진 코포레이션 | Inhibition of cyclooxygenase-2 activity |
| AU6147301A (en) | 2000-05-15 | 2001-11-26 | Celgene Corp | Compositions and methods for the treatment of colorectal cancer |
| DK1307197T3 (en) | 2000-05-15 | 2006-07-03 | Celgene Corp | Compositions for the treatment of cancer containing a topoisomerase inhibitor and thalidomide |
| US20030104573A1 (en) * | 2000-09-11 | 2003-06-05 | Shimkets Richard A. | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
| US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| WO2002064083A2 (en) * | 2000-11-30 | 2002-08-22 | The Children's Medical Center Corporation | Synthesis of 3-amino-thalidomide and its enantiomers |
| US20040121945A1 (en) * | 2000-12-15 | 2004-06-24 | Hong Liang | Compositions and methods for inhibiting endothelial cell proliferation |
| EP1226824A1 (en) * | 2001-01-24 | 2002-07-31 | TTY Biopharm Company Limited | Use of thalidomide for the treatment of hepatocellular carcinoma |
| US6632835B2 (en) | 2001-02-22 | 2003-10-14 | Nanodesign Inc. | Dibenzo[c]chromen-6-one derivatives as anti-cancer agents |
| EP1389203B8 (en) * | 2001-02-27 | 2010-03-10 | The Governement of the United States of America, represented by The Secretary Department of Health and Human services | Analogs of thalidomide as angiogenesis inhibitors |
| EP1389103A4 (en) * | 2001-04-23 | 2005-09-14 | Univ Virginia | Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents |
| CA2451942A1 (en) * | 2001-07-27 | 2003-02-13 | Munirathinam Sundaramoorthy | Crystallized structure of type iv collagen nc1 domain hexamer |
| DK1423115T3 (en) * | 2001-08-06 | 2009-06-15 | Childrens Medical Center | Nitrogen-substituted antiangiogenetic activity of thalidomide analogues |
| GB0125659D0 (en) * | 2001-10-25 | 2001-12-19 | Ssl Int Plc | Spermicides |
| AU2002357004A1 (en) * | 2001-11-20 | 2003-06-10 | Dendreon San Diego Llc | Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon |
| US20030139469A1 (en) * | 2002-01-23 | 2003-07-24 | The Regents Of The University Of California | Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation |
| AU2003220091B2 (en) * | 2002-03-08 | 2006-02-16 | Emory University | Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis |
| WO2003075860A2 (en) * | 2002-03-08 | 2003-09-18 | Abgent, Inc. | Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof |
| AU2003220685A1 (en) * | 2002-04-09 | 2003-10-27 | Greenville Hospital System | Metastasis modulating activity of highly sulfated oligosaccharides |
| USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
| US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
| EP2258363A1 (en) * | 2002-05-17 | 2010-12-08 | Celgene Corporation | Compositions for treatment of cancers |
| CN103495169B (en) | 2002-05-17 | 2016-06-22 | 细胞基因公司 | For treating and control the method and composition of multiple myeloma |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US20040001801A1 (en) * | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
| WO2004002418A2 (en) * | 2002-06-26 | 2004-01-08 | Entremed, Inc | Compositions and methods comprising protein activated receptor antagonists |
| EP2263697A3 (en) | 2002-07-15 | 2011-01-19 | Board of Regents, The University of Texas System | Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections |
| JP2005537282A (en) * | 2002-07-22 | 2005-12-08 | ケムジェネックス・ファーマシューティカルズ・リミテッド | Inhibition of angiogenesis by cephalotaxin alkaloids, and derivatives, compositions and methods of use thereof |
| GEP20074270B (en) * | 2002-07-23 | 2007-12-25 | Univ Michigan | Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies |
| US8404717B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
| US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| KR20050056247A (en) * | 2002-10-15 | 2005-06-14 | 셀진 코포레이션 | Method of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myelodysplastic syndromes |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| EP1900369A1 (en) | 2002-10-15 | 2008-03-19 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
| US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| EP1562597A4 (en) * | 2002-10-31 | 2008-05-14 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
| US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| ZA200503655B (en) | 2002-11-06 | 2006-08-30 | Celgene Corp | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| US8034831B2 (en) * | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| BR0316206A (en) * | 2002-11-12 | 2005-09-27 | Alcon Inc | Use of histone deacetylase inhibitors for the treatment of neovascular or edematous eye disorders |
| US7230012B2 (en) | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
| US9006267B2 (en) * | 2002-11-14 | 2015-04-14 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
| WO2008109433A2 (en) | 2007-03-02 | 2008-09-12 | The Cleveland Clinic Foundation | Anti-angiogenic peptides |
| US7517887B2 (en) * | 2003-04-09 | 2009-04-14 | General Atomics | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof |
| US7868011B2 (en) * | 2003-04-09 | 2011-01-11 | General Atomics | Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus |
| US7196093B2 (en) * | 2003-04-09 | 2007-03-27 | General Atomics | Reversible inhibitors of SAH hydrolase and uses thereof |
| DE10323898A1 (en) | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors |
| CA2527074A1 (en) * | 2003-05-28 | 2005-04-07 | Entremed, Inc. | Antiangiogenic agents |
| WO2005016326A2 (en) * | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| DK1648998T3 (en) | 2003-07-18 | 2015-01-05 | Amgen Inc | Specific binding agents for hepatocyte growth factor |
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| JP4943845B2 (en) * | 2003-09-17 | 2012-05-30 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Thalidomide analog |
| US8952895B2 (en) | 2011-06-03 | 2015-02-10 | Apple Inc. | Motion-based device operations |
| US20080027113A1 (en) * | 2003-09-23 | 2008-01-31 | Zeldis Jerome B | Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration |
| US7612096B2 (en) * | 2003-10-23 | 2009-11-03 | Celgene Corporation | Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline |
| AU2003286931A1 (en) * | 2003-11-06 | 2004-06-06 | Celgene Corporation | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases |
| AU2004288714A1 (en) | 2003-11-06 | 2005-05-26 | Celgene Corporation | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. |
| US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| WO2005055929A2 (en) * | 2003-12-02 | 2005-06-23 | Celgene Corporation | Methods and compositions for the treatment and management of hemoglobinopathy and anemia |
| US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| US7430276B2 (en) * | 2004-02-25 | 2008-09-30 | Nanodynamics-88 | Low dose X-ray mammography method |
| AU2005222934B2 (en) * | 2004-03-12 | 2010-06-17 | Entremed, Inc. | Antiangiogenic agents |
| EP2505200A1 (en) * | 2004-03-22 | 2012-10-03 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of scleroderma |
| US20050222209A1 (en) * | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| MXPA06011798A (en) * | 2004-04-14 | 2007-01-16 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes. |
| EP1744748A4 (en) * | 2004-04-14 | 2009-08-12 | Celgene Corp | Method of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myelodysplastic syndromes |
| MXPA06012278A (en) * | 2004-04-23 | 2007-01-31 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension. |
| JP2007533759A (en) * | 2004-04-23 | 2007-11-22 | セルジーン・コーポレーション | Composition comprising thalidomide for treatment and management of pulmonary hypertension and method of use thereof |
| CA2565215C (en) * | 2004-04-30 | 2014-04-15 | Biopheresis Technologies, Inc. | Method and system to remove soluble tnfr1, tnfr2, and il2 in patients |
| US7273890B1 (en) * | 2004-06-08 | 2007-09-25 | Sagittarius Life Science Corp. | ST104P, an anti-angiogenic agent |
| US20060063930A1 (en) * | 2004-08-20 | 2006-03-23 | Agoston Gregory E | Compositions and methods comprising proteinase activated receptor antagonists |
| AU2005282728A1 (en) * | 2004-09-03 | 2006-03-16 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines |
| CN101309585A (en) * | 2004-10-28 | 2008-11-19 | 细胞基因公司 | Methods and compositions using pde4 modulators for treatment and management of central nervous system injury |
| CA2588597A1 (en) * | 2004-11-23 | 2006-06-01 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
| CA2607228C (en) * | 2005-05-09 | 2014-09-16 | Biosphere Medical S.A. | Compositions and methods using microspheres and non-ionic contrast agents |
| US20060270707A1 (en) * | 2005-05-24 | 2006-11-30 | Zeldis Jerome B | Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus |
| US20080167272A1 (en) * | 2005-06-16 | 2008-07-10 | Auckland Uniservices Limited | Thalidomide metabolites and methods of use |
| PT1907373E (en) | 2005-06-30 | 2013-02-18 | Celgene Corp | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
| US20080279912A1 (en) * | 2005-07-12 | 2008-11-13 | Regents Of The University Of California Office Of Technology Transfer | Use of Cis-Epoxyeicosatrienoic Acids And Inhibitors of Soluble Epoxide Hydrolase to Alleviate Eye Disorders |
| US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
| US20070065514A1 (en) * | 2005-09-22 | 2007-03-22 | Howell Mark D | Method for enhancing immune responses in mammals |
| CN1939922B (en) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 5H-thiophene [3,4-C] pyrrole-4,6-diketone derivative for inhibiting cell release tumor necrosis factor |
| CA2624025A1 (en) * | 2005-10-14 | 2007-04-19 | F. Hoffmann-La Roche Ag | Regimen of administration for 5-(2-chlorophenyl)-1 ,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo [3, 4.-b] [1, 4] benzodiazepine |
| US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
| WO2007090127A2 (en) | 2006-01-30 | 2007-08-09 | Surgica Corporation | Compressible intravascular embolization particles and related methods and delivery systems |
| ATE520427T1 (en) * | 2006-01-30 | 2011-09-15 | Biosphere Medical Inc | POROUS INTRAVASCULAR EMBOLIZATION PARTICLES AND METHOD FOR THE PRODUCTION THEREOF |
| CA2646065C (en) * | 2006-03-20 | 2014-01-14 | Entremed, Inc. | Disease modifying anti-arthritic activity of 2-methoxyestradiol |
| US20070226632A1 (en) * | 2006-03-21 | 2007-09-27 | Nokia Corporation | Method, electronic device and computer program product for enhancing contact list functionality |
| CA2648216C (en) * | 2006-04-13 | 2016-06-07 | Michael Gutschow | Tetrahalogenated compounds useful as inhibitors of angiogenesis |
| US20080064876A1 (en) * | 2006-05-16 | 2008-03-13 | Muller George W | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| US20080051431A1 (en) * | 2006-05-26 | 2008-02-28 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds in combination therapy |
| KR20090014393A (en) * | 2006-05-26 | 2009-02-10 | 셀진 코포레이션 | Methods and compositions using immunomodulatory compounds in combination therapy |
| WO2008007979A1 (en) * | 2006-07-12 | 2008-01-17 | Auckland Uniservices Limited | (2,6-dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20121506A1 (en) | 2006-07-14 | 2012-11-26 | Amgen Inc | TRIAZOLOPYRIDINE COMPOUNDS AS C-MET INHIBITORS |
| EP2068877A4 (en) | 2006-07-19 | 2011-09-21 | Cleveland Clinic Foundation | Compounds and methods of modulating angiogenesis |
| CL2007002218A1 (en) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | USE OF 3- (4-AMINO-1-OXO-1,3-DIHIDRO-ISOINDOL-2-IL) -PIPERIDINE 2,6-DIONA FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF LAYER CELL LYMPHOMA. |
| CN101138634A (en) * | 2006-09-07 | 2008-03-12 | 于保法 | Composition for treating tumour |
| US20080075690A1 (en) * | 2006-09-22 | 2008-03-27 | Mark Douglas Howell | Method for enhancing immune responses in mammals |
| WO2008103277A2 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| CN103285015B (en) * | 2007-04-13 | 2016-04-27 | 化学基因制药公司 | Oral cephalotaxine dosage forms |
| WO2009020590A1 (en) * | 2007-08-07 | 2009-02-12 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
| SG10201500328QA (en) | 2007-08-21 | 2015-03-30 | Amgen Inc | Human c-fms antigen binding proteins |
| JP2010539245A (en) | 2007-09-14 | 2010-12-16 | 日東電工株式会社 | Drug carrier |
| US11331294B2 (en) | 2007-09-26 | 2022-05-17 | Indiana University Research And Technology Corporation | Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of bladder cancer |
| CA2700365C (en) * | 2007-09-26 | 2016-07-05 | Indiana University Research And Technology Corporation | Benzoquinone derivative e3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis |
| EP2219672B1 (en) | 2007-11-09 | 2016-02-17 | Peregrine Pharmaceuticals, Inc. | Anti-vegf antibody compositions and methods |
| US20090137631A1 (en) * | 2007-11-22 | 2009-05-28 | National Yang-Ming University | Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression |
| SG10201510586PA (en) | 2008-06-30 | 2016-01-28 | Mesoblast Inc | Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy |
| EP2323679A4 (en) | 2008-07-25 | 2012-08-22 | Univ Colorado | Clip inhibitors and methods of modulating immune function |
| JP2012507562A (en) * | 2008-10-30 | 2012-03-29 | ダビド リウ | Microspherical porous biocompatible scaffold and manufacturing method and apparatus thereof |
| AU2010249615B2 (en) | 2009-05-19 | 2013-07-18 | Celgene Corporation | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
| WO2010137547A1 (en) | 2009-05-25 | 2010-12-02 | 国立大学法人東京工業大学 | Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells |
| GB0914330D0 (en) | 2009-08-17 | 2009-09-30 | Univ Dublin City | A method of predicting response to thalidomide in multiple myeloma patients |
| US20120183546A1 (en) | 2009-09-23 | 2012-07-19 | Amgen Inc. | Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane |
| US20140031325A1 (en) | 2010-12-06 | 2014-01-30 | Celgene Corporation | Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma |
| WO2012079088A2 (en) | 2010-12-10 | 2012-06-14 | The Johns Hopkins University | Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases |
| PT2688887E (en) | 2011-03-23 | 2015-07-06 | Amgen Inc | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| EP2702410A2 (en) | 2011-04-29 | 2014-03-05 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| MX358726B (en) | 2011-06-29 | 2018-09-03 | Amgen Inc | Predictive biomarker of survival in the treatment of renal cell carcinoma. |
| WO2013025939A2 (en) | 2011-08-16 | 2013-02-21 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| US20130058926A1 (en) * | 2011-08-30 | 2013-03-07 | Shiseido Company, Ltd. | Method for alleviating and/or preventing skin reddening |
| US8927725B2 (en) | 2011-12-02 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thio compounds |
| US9085551B2 (en) | 2012-02-21 | 2015-07-21 | Celgene Corporation | Solid forms of 3-(4-nitro-1-oxisoindolin-2-yl)piperidine-2,6-dione |
| AR090263A1 (en) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME |
| JP6318152B2 (en) * | 2012-06-29 | 2018-04-25 | セルジーン コーポレイション | Methods for determining drug efficacy using cereblon-related proteins |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| WO2014124280A1 (en) | 2013-02-08 | 2014-08-14 | Institute For Myeloma & Bone Cancer Research | Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma |
| RS62080B1 (en) | 2013-02-13 | 2021-07-30 | Cartiheal 2009 Ltd | Solid substrates for promoting cell and tissue growth |
| ES2837628T3 (en) | 2013-03-15 | 2021-07-01 | Celgene Corp | Modified T lymphocytes |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| AU2015210999A1 (en) | 2014-01-29 | 2016-07-21 | Otsuka Pharmaceutical Co., Ltd. | Device-based risk management of a therapeutic |
| ES2946179T3 (en) | 2014-05-28 | 2023-07-13 | Onco Tracker Inc | Antineoplastic effects of JAK2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| ES2843973T3 (en) | 2014-06-27 | 2021-07-21 | Celgene Corp | Compositions and methods to induce conformational changes in cereblon and other E3 ubiquitin ligases |
| LT3182996T (en) | 2014-08-22 | 2023-03-10 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
| PT3643709T (en) | 2014-10-30 | 2021-12-20 | Kangpu Biopharmaceuticals Ltd | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof |
| US11110303B2 (en) | 2014-11-26 | 2021-09-07 | Baofa Yu | Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy |
| WO2016209972A1 (en) | 2015-06-26 | 2016-12-29 | Amgen Inc. | Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor |
| JP2018527302A (en) | 2015-06-26 | 2018-09-20 | セルジーン コーポレイション | Method of treating Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds and use of biomarkers |
| WO2017019496A1 (en) | 2015-07-24 | 2017-02-02 | Berenson James Richard | Gamma secretase modulators for the treatment of immune system dysfunction |
| AU2016330967B2 (en) * | 2015-09-30 | 2021-03-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thalidomide analogs and methods of use |
| TWI747846B (en) | 2015-10-21 | 2021-12-01 | 日商大塚製藥股份有限公司 | Benzolactam compounds |
| WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| JP7011600B2 (en) | 2016-01-12 | 2022-01-26 | ジェイムズ リチャード ベレンソン， | Improved method for monitoring the immune status of a subject |
| EP3436072A4 (en) * | 2016-03-31 | 2019-11-06 | Omeros Corporation | Methods for inhibiting angiogenesis in a subject in need thereof |
| AU2017368332A1 (en) | 2016-12-03 | 2019-06-13 | Juno Therapeutics, Inc. | Methods for modulation of CAR-T cells |
| ES2961666T3 (en) | 2016-12-03 | 2024-03-13 | Juno Therapeutics Inc | Methods to determine CAR-T cell dosage |
| CN116606261A (en) | 2016-12-22 | 2023-08-18 | 美国安进公司 | KRAS G12C inhibitors and methods of use thereof |
| US10786471B2 (en) | 2017-02-06 | 2020-09-29 | Massachusetts Institute Of Technology | Methods and products related to glutaminase inhibitors |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| WO2018204427A1 (en) | 2017-05-01 | 2018-11-08 | Juno Therapeutics, Inc. | Combination of a cell therapy and an immunomodulatory compound |
| JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| US10093647B1 (en) | 2017-05-26 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof |
| KR20200054160A (en) | 2017-06-02 | 2020-05-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | Preparation and method of articles for treatment with adoptive cell therapy |
| EP3639028A4 (en) | 2017-06-13 | 2021-04-14 | Inc. Onco Tracker | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
| US20220225597A1 (en) | 2017-06-29 | 2022-07-21 | Juno Therapeutics, Inc. | Mouse model for assessing toxicities associated with immunotherapies |
| US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| CN116003405A (en) | 2017-09-08 | 2023-04-25 | 美国安进公司 | Inhibitors of KRAS G12C and methods of use thereof |
| US10093648B1 (en) | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof |
| US10093649B1 (en) | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof |
| WO2019089969A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
| US20210132042A1 (en) | 2017-11-01 | 2021-05-06 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| MA51210A (en) | 2017-12-01 | 2020-10-07 | Juno Therapeutics Inc | METHODS FOR DOSING AND MODULATING GENETICALLY MODIFIED CELLS |
| JP2021506260A (en) | 2017-12-15 | 2021-02-22 | ジュノー セラピューティクス インコーポレイテッド | Anti-CCT5 binding molecule and how to use it |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| WO2019210080A1 (en) * | 2018-04-25 | 2019-10-31 | The Regents Of The University Of California | Methods and compositions for skeletal and neurological disorders |
| MA52496A (en) | 2018-05-04 | 2021-03-10 | Amgen Inc | KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE |
| CA3098574A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| CA3099045A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
| MA52765A (en) | 2018-06-01 | 2021-04-14 | Amgen Inc | KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE |
| EP3802537A1 (en) | 2018-06-11 | 2021-04-14 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
| US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
| AU2019309894A1 (en) | 2018-07-27 | 2021-01-28 | Biotheryx, Inc. | Bifunctional compounds as CDK modulators |
| MX2021005366A (en) | 2018-11-08 | 2021-09-10 | Juno Therapeutics Inc | Methods and combinations for treatment and t cell modulation. |
| JP2020090482A (en) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Improved synthesis of key intermediate of kras g12c inhibitor compound |
| CN113271963A (en) | 2018-11-16 | 2021-08-17 | 朱诺治疗学股份有限公司 | Methods of administering engineered T cells for treatment of B cell malignancies |
| JP7377679B2 (en) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer |
| EP3883565A1 (en) | 2018-11-19 | 2021-09-29 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| AU2019387497A1 (en) | 2018-11-30 | 2021-06-24 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| WO2020132649A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| AU2019401495A1 (en) | 2018-12-20 | 2021-06-24 | Amgen Inc. | Heteroaryl amides useful as KIF18A inhibitors |
| AU2019403488A1 (en) | 2018-12-20 | 2021-06-24 | Amgen Inc. | KIF18A inhibitors |
| EP3897852A1 (en) | 2018-12-20 | 2021-10-27 | Amgen Inc. | Kif18a inhibitors |
| WO2020160050A1 (en) | 2019-01-29 | 2020-08-06 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
| SG11202109036WA (en) | 2019-03-01 | 2021-09-29 | Revolution Medicines Inc | Bicyclic heteroaryl compounds and uses thereof |
| CA3130083A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| CA3140392A1 (en) | 2019-05-21 | 2020-11-26 | Amgen Inc. | Solid state forms |
| MX2022001302A (en) | 2019-08-02 | 2022-03-02 | Amgen Inc | Pyridine derivatives as kif18a inhibitors. |
| US20220289724A1 (en) | 2019-08-02 | 2022-09-15 | Amgen Inc. | Kif18a inhibitors |
| CA3147451A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| WO2021081212A1 (en) | 2019-10-24 | 2021-04-29 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
| CN115873067A (en) | 2019-11-04 | 2023-03-31 | 锐新医药公司 | RAS inhibitors |
| EP4054720A1 (en) | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2021092115A1 (en) | 2019-11-08 | 2021-05-14 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| US20230192681A1 (en) | 2019-11-14 | 2023-06-22 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| MX2022005726A (en) | 2019-11-14 | 2022-06-09 | Amgen Inc | Improved synthesis of kras g12c inhibitor compound. |
| CN114980976A (en) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | Covalent RAS inhibitors and uses thereof |
| BR112022010086A2 (en) | 2020-01-07 | 2022-09-06 | Revolution Medicines Inc | SHP2 INHIBITOR DOSAGE AND CANCER TREATMENT METHODS |
| US11897930B2 (en) | 2020-04-28 | 2024-02-13 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| AU2021293228A1 (en) | 2020-06-18 | 2023-02-09 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors |
| IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| PE20231207A1 (en) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | INDOLIC DERIVATIVES AS RAS INHIBITORS IN CANCER TREATMENT |
| EP4267250A1 (en) | 2020-12-22 | 2023-11-01 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
| AR125787A1 (en) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | RAS INHIBITORS |
| PE20240088A1 (en) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | RAS INHIBITORS |
| EP4334324A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2830991A (en) * | 1954-05-17 | 1958-04-15 | Gruenenthal Chemie | Products of the amino-piperidine-2-6-dione series |
| GB768821A (en) | 1954-05-17 | 1957-02-20 | Gruenenthal Chemie | Novel products of the amino-piperidine-2, 6-dione series |
| US3142672A (en) * | 1957-09-03 | 1964-07-28 | Takeda Pharmaceutical | Derivatives of nu-alpha-phenyl-and nu-alpha-biphenylylbutyric acids and amino sugars |
| US3560495A (en) * | 1965-05-08 | 1971-02-02 | Ernst Frankus | 1-heterocyclic amino methyl or 1-heterocyclic hydrazino methyl-3-phthalimido or (3',6'-dithia-3',4',5',6'-tetrahydrophthalimido)-pyrrolidinediones-2,5 or piperidinediones-2,6 |
| US3563986A (en) * | 1965-10-12 | 1971-02-16 | Ernst Frankus | 4 - phthalimido - n - heterocyclic amino methyl or piperidino hydrazino piperidine diones 2,6 |
| DE1670551B2 (en) * | 1965-10-30 | 1973-01-25 | SALT TRISUBSTITUTED S-TRIAZINE | |
| AT278739B (en) * | 1966-11-08 | 1970-02-10 | Kwizda Fa F Johann | Process for the preparation of new anhydrides and imides of substituted dicarboxylic acids |
| US3705162A (en) * | 1967-07-01 | 1972-12-05 | Gruenenthal Chemie | 4-phthalimidine glutarimides |
| IL67646A0 (en) * | 1982-01-15 | 1983-05-15 | Lilly Co Eli | Ascorbic acid ethers and related compounds |
| US4552888A (en) * | 1982-01-15 | 1985-11-12 | Eli Lilly And Company | Ascorbic acid ethers in angiogene |
| US4994443A (en) * | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US5001116A (en) * | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| JP2544136B2 (en) * | 1986-05-23 | 1996-10-16 | 第一製薬株式会社 | Angiogenesis inhibitor and antitumor agent containing sulfated polysaccharide DS4152 |
| US4808402A (en) * | 1987-05-29 | 1989-02-28 | Northwestern University | Method and compositions for modulating neovascularization |
| ES2059571T3 (en) * | 1988-01-19 | 1994-11-16 | Takeda Chemical Industries Ltd | FUMAGILINA AS AN ANGIOSTATIC AGENT. |
| AT393221B (en) * | 1988-02-03 | 1991-09-10 | Leopold Pharma Gmbh | AGENT WITH DESTROYING EFFECT ON MALIGNE TUMORS, METHOD FOR THE PRODUCTION THEREOF AND PREPARATION FOR USE IN THE THERAPY OF CANCER DISEASES |
| US5021404A (en) * | 1988-04-20 | 1991-06-04 | The Children's Medical Center Corporation | Angiostatic collagen modulators |
| EP0357061B1 (en) * | 1988-09-01 | 1994-06-08 | Takeda Chemical Industries, Ltd. | Angiogenesis inhibitory agent |
| US5049154A (en) * | 1989-08-07 | 1991-09-17 | Berkshire Research & Development, Inc. | Adjustable intra-luminal valvulotome |
| JPH03109324A (en) * | 1989-09-22 | 1991-05-09 | Microbial Chem Res Found | Vascularization inhibitor |
| GB9000644D0 (en) * | 1990-01-11 | 1990-03-14 | Erba Carlo Spa | New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds |
| US5192744A (en) | 1990-01-12 | 1993-03-09 | Northwestern University | Method of inhibiting angiogenesis of tumors |
| KR0166088B1 (en) * | 1990-01-23 | 1999-01-15 | . | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5405851A (en) * | 1990-06-19 | 1995-04-11 | Burroughs Wellcome Co. | Pharmaceutical compounds |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| WO1992014455A1 (en) | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
| DK0580641T3 (en) * | 1991-04-17 | 1997-01-20 | Gruenenthal Gmbh | Novel thalidomide derivatives, a process for their preparation and their use in pharmaceuticals |
| US5679696A (en) | 1992-07-28 | 1997-10-21 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group |
| US6114355A (en) | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
| US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| DE4320157A1 (en) | 1993-06-18 | 1994-12-22 | Bayer Ag | Use of 1,2,4-dithiazolium salts as chemotherapeutic agents |
| US5605914A (en) | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
| AU7376494A (en) | 1993-08-04 | 1995-02-28 | Andrulis Pharmaceuticals Corporation | Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents |
| US5434170A (en) | 1993-12-23 | 1995-07-18 | Andrulis Pharmaceuticals Corp. | Method for treating neurocognitive disorders |
| US5405855A (en) | 1993-12-23 | 1995-04-11 | Andrulis Pharmaceuticals Corp. | Treatment of insulin resistant diabetes with thalidomine |
| US5443824A (en) | 1994-03-14 | 1995-08-22 | Piacquadio; Daniel J. | Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions |
| US5948403A (en) | 1995-03-17 | 1999-09-07 | Toray Industries, Inc. | Corneal angiogenesis inhibitor |
| US5643915A (en) | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
| US5731325A (en) | 1995-06-06 | 1998-03-24 | Andrulis Pharmaceuticals Corp. | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents |
| US5654312A (en) | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
| US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| CN1342146A (en) | 1999-03-18 | 2002-03-27 | 塞尔基因公司 | Substituted 1-oxo-and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels |
-
1993
- 1993-12-15 US US08/168,817 patent/US5629327A/en not_active Expired - Lifetime
-
1994
- 1994-02-24 EP EP02012280A patent/EP1245229A3/en not_active Withdrawn
- 1994-02-24 WO PCT/US1994/001971 patent/WO1994020085A1/en active IP Right Grant
- 1994-02-24 NZ NZ262676A patent/NZ262676A/en not_active IP Right Cessation
- 1994-02-24 AT AT02011928T patent/ATE304356T1/en not_active IP Right Cessation
- 1994-02-24 ES ES02011928T patent/ES2245711T3/en not_active Expired - Lifetime
- 1994-02-24 DE DE69430796T patent/DE69430796T2/en not_active Expired - Lifetime
- 1994-02-24 AT AT94909773T patent/ATE218865T1/en active
- 1994-02-24 DK DK02011928T patent/DK1264597T3/en active
- 1994-02-24 DE DE122008000044C patent/DE122008000044I2/de active Active
- 1994-02-24 DE DE69434490T patent/DE69434490T2/en not_active Expired - Lifetime
- 1994-02-24 CA CA002157288A patent/CA2157288C/en not_active Expired - Lifetime
- 1994-02-24 CA CA002342974A patent/CA2342974C/en not_active Expired - Lifetime
- 1994-02-24 EP EP94909773A patent/EP0688211B1/en not_active Expired - Lifetime
- 1994-02-24 CA CA2512926A patent/CA2512926C/en not_active Expired - Lifetime
- 1994-02-24 EP EP05002523A patent/EP1537870A3/en not_active Withdrawn
- 1994-02-24 JP JP6520046A patent/JPH08507767A/en not_active Withdrawn
- 1994-02-24 NZ NZ336527A patent/NZ336527A/en not_active IP Right Cessation
- 1994-02-24 KR KR1019950703700A patent/KR100506043B1/en not_active IP Right Cessation
- 1994-02-24 PT PT94909773T patent/PT688211E/en unknown
- 1994-02-24 NZ NZ535671A patent/NZ535671A/en not_active IP Right Cessation
- 1994-02-24 DK DK94909773T patent/DK0688211T3/en active
- 1994-02-24 ES ES94909773T patent/ES2174873T3/en not_active Expired - Lifetime
- 1994-02-24 AU AU62486/94A patent/AU676722B2/en not_active Expired
- 1994-02-24 EP EP02011928A patent/EP1264597B1/en not_active Revoked
- 1994-02-24 NZ NZ535670A patent/NZ535670A/en not_active IP Right Cessation
- 1994-03-01 BR BR9400764A patent/BR9400764A/en not_active Application Discontinuation
- 1994-03-01 CO CO94008093A patent/CO4230017A1/en unknown
- 1994-03-01 PE PE1994237564A patent/PE10095A1/en not_active Application Discontinuation
-
1995
- 1995-01-13 US US08/371,987 patent/US5593990A/en not_active Expired - Lifetime
- 1995-06-06 US US08/468,792 patent/US5712291A/en not_active Ceased
-
1997
- 1997-08-22 US US08/918,610 patent/US6235756B1/en not_active Expired - Lifetime
- 1997-10-16 US US08/950,673 patent/US6071948A/en not_active Expired - Lifetime
-
2000
- 2000-04-07 US US09/545,139 patent/US6469045B1/en not_active Expired - Fee Related
- 2000-11-09 US US09/710,533 patent/US6420414B1/en not_active Expired - Lifetime
-
2001
- 2001-02-26 JP JP2001050214A patent/JP4065373B2/en not_active Expired - Lifetime
- 2001-07-05 US US09/899,318 patent/US20010056113A1/en not_active Abandoned
- 2001-09-28 US US09/966,895 patent/US20020049231A1/en not_active Abandoned
- 2001-10-24 US US10/001,183 patent/US20020119956A1/en not_active Abandoned
- 2001-12-12 US US10/015,252 patent/US20020052398A1/en not_active Abandoned
- 2001-12-19 US US10/026,037 patent/US6977268B2/en not_active Expired - Fee Related
- 2001-12-20 US US10/026,291 patent/US20020061911A1/en not_active Abandoned
-
2002
- 2002-06-11 US US10/167,531 patent/US20020161024A1/en not_active Abandoned
- 2002-12-13 US US10/319,389 patent/US20030187024A1/en not_active Abandoned
-
2003
- 2003-01-14 US US10/341,928 patent/US20030176463A1/en not_active Abandoned
- 2003-06-10 HK HK03104072A patent/HK1052865A1/en not_active IP Right Cessation
-
2004
- 2004-07-28 JP JP2004220584A patent/JP2004359693A/en active Pending
-
2005
- 2005-03-31 US US11/096,155 patent/US7723361B2/en not_active Expired - Fee Related
-
2006
- 2006-09-22 US US11/525,346 patent/US8012996B2/en not_active Expired - Fee Related
-
2007
- 2007-11-07 JP JP2007289175A patent/JP2008088182A/en active Pending
-
2008
- 2008-08-01 FR FR08C0036C patent/FR08C0036I2/fr active Active
- 2008-08-20 LU LU91471C patent/LU91471I2/en unknown
- 2008-09-01 NL NL300358C patent/NL300358I2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2512926C (en) | Methods and compositions for inhibition of angiogenesis | |
| US6114355A (en) | Methods and compositions for inhibition of angiogenesis | |
| US6518298B2 (en) | Methods and compositions for inhibition of angiogenesis with EM-138 | |
| US20020161023A1 (en) | Method of treating diseases using 3-amino thalidomide | |
| EP1920773A1 (en) | Compositions for inhibition of anglogenesis | |
| US20120142734A1 (en) | Methods for treating tumors with thalidomide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20140224 |